Document:

License Agreement between the Registrant and Medtronic

 Exhibit 10.24 
 LICENSE AGREEMENT 
 This License Agreement is made this 9th day of August, 1999 (the “Effective
Date”), by and among Virtuel Medical Devices, Inc. (“Licensee”), a Delaware corporation, and Medtronic, Inc. (“Medtronic”), a Minnesota corporation. 
 RECITALS: 
 A. Medtronic has developed certain technology related to “Wet
Electrode Products” (as defined below) and a “Wet Electrode Generator” (as defined below). 
 B. Medtronic desires to grant,
and Licensee desires to obtain, an exclusive, worldwide royalty-bearing license to the “Subject Technology” (as defined below) in certain fields of use in accordance with all of the terms of this Agreement. 
 NOW, THEREFORE, the parties hereto agree as follows: 
 ARTICLE 1 
 Definitions 
 As used herein, the following definitions and terms shall have the designated meanings: 
 1.1. “Action” shall mean
any claim, action, suit or proceeding, whether civil or criminal, or in law or equity and including any arbitration. 
 1.2.
“Affiliate” of any entity shall mean any other entity that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the first entity. Control shall mean owning at
least 50 percent of the total voting power of the entity. 
 1.3. “Confidential Information” shall mean all information
provided to a party (the “receiving party”) by a party (the “disclosing party”) or its employees, agents or consultants, excluding any information which: 
 (a) is or becomes publicly available through no fault of the receiving party; or 
 (b) can be reasonably demonstrated to have been known to the receiving party independently of any disclosure of “Confidential Information” by
the disclosing party or its employees, agents or consultants; or 
 (c) is disclosed to the receiving party by a third party who, to the best
of the receiving party’s knowledge, is lawfully in possession of the same and has the right to make such disclosure; or 
  
  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 (d) has been independently developed by the receiving party without reference to the information
disclosed to the receiving party by the disclosing party or its employees, agents or consultants. 
 All “Confidential Information” disclosed to
the receiving party under this Agreement shall ultimately be in writing and bear a legend “Proprietary”, “Confidential” or words of similar import. Accordingly, all “Confidential Information” disclosed in any manner
other than writing shall be preceded by an oral statement indicating that the information is proprietary or confidential and shall be followed by transmittal of a reasonably detailed written summary of the information provided to the receiving party
with identification as “Confidential Information” designated as above within thirty (30) days. 
 1.4.
“Expiration” or “Expired” shall mean with respect to a particular patent, the patent’s expiration, abandonment, cancellation, disclaimer, award to another party other than Medtronic or an Affiliate of Medtronic
in an interference proceeding, or declaration of invalidity or unenforceability of all claims thereof by a court or other authority of competent jurisdiction (including a re-examination or reissue proceeding) from which no further appeal has or can
be taken. References to an “Unexpired” patent shall mean a patent that has not Expired. 
 1.5. “Field of Use”
shall mean any [*] applications in [*] (including, but not limited to, [*] during and following [*] other than and hereby expressly excluding applications relating to: (i) the [*] and [*]: (ii) the vertebrae, spinal column and brain and
the head and neck and [*] and [*] and [*] thereof; (iii) the [*], the [*] and the [*] of the [*]; (iv) the [*]; and (v) the [*] when accessed by [*] means. Without limitation of the forgoing, the Field of Use shall also specifically
exclude application in the fields of [*] (excluding [*] of the [*] during and following [*]) and [*]. 
 1.6. “Law” shall
mean any law, regulation, rule, ordinance or governmental regulation or guideline or any judicial, administrative or arbitration, order or award, judgment, writ, injunction or decree which is applicable to a person or by which a person is bound.

 1.7. “Licensed Products” shall mean Wet Electrode Products and Wet Electrode Generators, the manufacture, use or sale of
which uses or incorporates any of the Subject Technology. 
 1.8. “Net Sales” of Licensed Products for a particular period
shall mean the amounts that Licensee or any sublicensee, Affiliate or third party permitted under Section 2.2 invoices third parties (eliminating transactions between Affiliates) for sales of Licensed Products during such period, excluding
sales, use or excise tax, freight, duty or insurance included therein, and credits or repayments due to rejection, defect or return. If Licensee or any sublicensee, Affiliate or third party permitted under Section 2.2 sells at a single price or
rate a packaged combination of products, not all of which if sold individually would be Licensed Products, then “Net Sales” of Licensed Products with respect to such sales of packaged products shall equal the total sales price of the
packaged combination multiplied by the ratio of the individual retail list price of the Licensed Products contained in the packaged combination to the sum of all individual retail list prices of every item in the packaged combination (if all of such
items were sold separately). If all such items are not sold separately, any item not sold separately shall have a price attributed to it for purposes of this definition consistent with pricing of similar products or their functional equivalents.
Without limitation of the foregoing, Net Sales shall include all transfers of 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 2 

 Licensed Products that Licensee or any sublicensee, Affiliate or third party permitted under Section 2.2 records as
a sale pursuant to generally accepted accounting principles consistently applied. Net Sales which are denominated in currencies other than U.S. Dollars shall be converted into U.S. Dollars on a monthly basis at the average of the applicable daily
exchange rates listed in the Wall Street Journal for the calendar month in which such Net Sales occurred, or on such other basis to which the parties may hereafter mutually agree. 
 1.9. “Product Liability Claims” shall mean claims for personal injury or death based on alleged breach of product warranty, strict
liability in tort, or negligent product design or manufacture. 
 1.10. “Quarter” means each three-month period ending
March 31, June 30, September 30, and December 31. 
 1.11. “Subject Technology” shall mean
(i) the issued patents, and patents arising out of the patent applications, listed on Exhibit A hereto, (ii) all reissues, continuations, continuations-in-part, extensions, reexaminations, and foreign counterparts thereof, (iii) all
invention disclosures, trade secrets and know-how owned by Medtronic prior to the date of this Agreement which relate specifically to the Wet Electrode Products and Wet Electrode Generators disclosed in the patents and the patent applications listed
on Exhibit A, and (iv) those improvements, enhancements and modifications defined in Section 2.6(c). The Subject Technology does not include any trademarks, trade names or service marks owned or used by Medtronic. 
 1.12. “Territory” shall mean the entire world. 
 1.13. “Wet Electrode Generator(s)” shall mean the medical generators primarily intended to provide power directly to Wet Electrode Products, in the Field of Use. 
 1.14. “Wet Electrode Products” shall mean medical blades, forceps or rollerballs that employ an electrode to deliver radio frequency
energy and an electrically conductive fluid between the electrode and the surface of living tissue to apply radio frequency energy in medical applications, in the Field of Use. Wet Electrode Products specifically exclude any interstitial needle or
intraluminal wire devices or products. 
 ARTICLE 2 
 License; Term and Termination 
 2.1. License Grant. Subject to the terms and provisions
hereof, Medtronic hereby grants to Licensee (a) a royalty-bearing, and exclusive license under the Subject Technology to make, have made, use and sell Wet Electrode Products in the Field of Use that are Licensed Products throughout the
Territory and (b) a royalty-bearing and non-exclusive license under the Subject Technology to make, have made, use and sell Wet Electrode Generators in the Field of Use that are Licensed Products throughout the Territory. 
 2.2. Sublicensing and Distribution. Licensee shall have the right to sublicense its rights under Section 2.1 and to enter into distribution,
OEM and other relationships with third parties with respect to the Licensed Products in the Field of Use, provided that 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 3 

 (i) such sublicense or other agreement with a sublicensee or third party or an Affiliate of Licensee (“Other
Agreement”) shall obligate such sublicensee or third party or an Affiliate of Licensee to assume and abide by all duties, obligations and restrictions provided under this Agreement and Licensee shall cause such sublicensee or third party or an
Affiliate of Licensee to comply with all of Licensee’s duties, obligations and restrictions hereunder, (ii) within thirty (30) days of execution of an Other Agreement, Licensee shall provide a copy of such Other Agreement to
Medtronic, (iii) any such sublicense or third party relationship granted by Licensee shall terminate automatically upon the termination of this Agreement, or shall be modified, if applicable, to become non-exclusive if Medtronic exercises its
rights under Section 4.4, and (iv) the royalty rate due from such sublicensee or third party of an Affiliate of Licensee under an Other Agreement shall at no time be less than the royalty rate due Medtronic under Section 3.2 of the
Agreement. Prior to termination, Licensee shall be responsible for: (i) the payment to Medtronic of all royalties based upon the Net Sales of License Products by such sublicensees or such third parties or by Licensee’s Affiliates; and
(ii) the performance of all of the obligations of such sublicensees or such third parties or by Licensee’s Affiliates herein. 
 2.3. Term of License. Unless otherwise terminated under provisions of this Article 2, this Agreement and the licenses granted under Sections 2.1 and 2.2 shall continue until such time as (i) all of the patents (including patents
arising out of the patent applications listed on Exhibit A) included within the Subject Technology (and all extensions thereof) have Expired or (ii) ten (10) years from the first commercial sale of a Licensed Product, whichever is longer.

 2.4. Termination. 
 (a)
If Licensee or any sublicensee, Affiliate or third party permitted under Section 2.2 breaches any of the material terms, conditions or agreements of this Agreement (including failure to restrict sales of Licensed Products and other activities
hereunder to the Field of Use), then Medtronic may terminate this Agreement, at its option and without prejudice to any of its other legal and equitable rights and remedies, including, but not limited to, seeking monetary damages and/or an
injunction, by giving Licensee sixty (60) days notice in writing, particularly specifying the breach. Such notice of termination shall not be effective if Licensee cures the specified breach within such sixty (60) day period. During such
60-day period, one or more executive officers of each party (meaning for purposes hereunder any vice president or higher level officer) shall meet or correspond to discuss such alleged breach and/or attempted cure thereof, and attempt in good faith
to resolve any dispute between the parties with respect thereto; provided that if any such dispute is not resolved to Medtronic’s satisfaction, then Medtronic may terminate this Agreement without prejudice to any of its other legal and
equitable rights and remedies including, but not limited to, seeking monetary damages and/or an injunction. If Licensee cures the breach during the 60-day period but, within one (1) year thereafter, the same or a substantially similar breach
occurs, then the parties shall determine, in good faith, a mutually agreed plan to address the conditions causing such breaches and to avoid or minimize future occurrences of such breach and Licensee thereafter shall use reasonable commercial
efforts to implement such plan, if no such mutual agreement is reached within sixty (60) days of notice of such breach, then Medtronic may terminate this Agreement, at its option and without prejudice to any of its other legal and equitable
rights and remedies, including, but not limited to, 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 4 

 seeking monetary damages and/or an injunction, by giving written notice to Licensee and without providing further
opportunity to cure such breach. Licensee may terminate this Agreement at any time in its discretion upon sixty (60) days’ prior written notice. Termination of this Agreement shall not affect Licensee’s obligation to pay Royalties
with respect to Net Sales of Licensed Products made prior to such termination and shall not result in any refund to Licensee of any consideration previously paid to Medtronic. The parties acknowledge that, with respect to any other breaches by
Licensee or by any sublicensee, Affiliate or third party permitted under Section 2.2 of the terms, conditions or agreements of this Agreement, Medtronic may pursue its full legal and equitable rights and remedies against Licensee, including,
but not limited to, seeking monetary damages and/or an injunction. 
 (b) Either party may, by written notice to the other party (which
notice shall be effective upon receipt), terminate this Agreement in the event that such other party becomes insolvent, makes an assignment for the benefit of creditors, goes into liquidation or receivership or otherwise loses legal control of its
business. 
 (c) The parties acknowledge and agree that all rights and licenses granted pursuant to this Agreement are, and shall otherwise
be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(52) of the Bankruptcy Code, and that each party, as a licensee hereunder, shall
retain and may fully exercise all of its rights and elections under the Bankruptcy Code. 
 2.5. Delivery and Return of Confidential
Information. Upon termination of this Agreement or the licenses granted hereunder as provided herein, each party shall within 30 days of such termination return to the other party all of the other party’s Confidential Information.
Notwithstanding the foregoing each party shall have the right to retain one copy of such other party’s Confidential Information in its legal department files for archival purposes only. 
 2.6. Know-How Transfer; Access to Medtronic’s Employees and Consultant. 
 (a) Any expenses associated with the disclosure of know-how included within the Subject Technology to Licensee from SeaMed, Inc. relating to the Wet
Electrode Generator shall be the sole responsibility of Licensee. 
 (b) Promptly after the Effective Date, Medtronic shall provide to
Licensee copies of all tangible Subject Technology not previously disclosed to Licensee, including without limitation, those materials described on Exhibit B. 
 (c) Upon reasonable notice by Licensee to Medtronic, during the first three (3) months after execution of the Agreement, Medtronic will use reasonable efforts to obtain the services of [*], and make available the
following Medtronic employees: [*] and [*], available to meet with Licensee, subject to such individuals’ other commitments and schedules, for up to twenty hours each in the case of [*] (in the presence of one or more Medtronic representatives)
and [*] and up to ten hours for Mr. [*], to disclose to Licensee on Medtronic’s behalf those trade secrets and know-how included within the Subject Technology to allow Licensee to better understand and practice the inventions disclosed
therein to which the licenses under this Agreement pertain. Licensee shall pay [*] such amount as [*] and Licensee may mutually agree for the foregoing efforts of [*] and reimburse such individuals for any 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 5 

 reasonable travel and lodging expenses, if any, incurred by them for the purposes of such disclosure. Licensee shall also
reimburse Medtronic for any animal lab expenses relating to such disclosure incurred after the date of execution of this Agreement. No such disclosures by, nor payment to, such individuals shall be deemed to amend, negate, or otherwise modify the
exclusive consulting or employment relationship between such individuals, as the case may be, and Medtronic or to transfer or otherwise grant any rights to Licensee other than those rights to the Subject Technology specifically set forth in this
Agreement. The parties agree that, if desired by Licensee and [*], Licensee may enter into a formal consulting relationship with [*] permitting [*] to provide paid consulting services to Licensee, in addition to any such services provided to
Medtronic, concerning the Licensed Products in the Field of Use, subject to Medtronic’s approval, which approval shall not be unreasonably withheld. Licensee and Medtronic agree that any improvements, enhancements or modifications to the
Subject Technology developed, conceived or made by [*]: (i) while [*] is subject to a consulting relationship with Licensee; or (ii) to which Medtronic has ownership rights pursuant to its consulting agreement with [*], shall be deemed to
be owned by, and title thereto shall be transferred to, Medtronic and shall be deemed to be part of the Subject Technology, and as such shall be subject to Licensee’s rights hereunder. 
 (d) Medtronic shall provide written waivers from any non-compete and confidentiality obligations of [*] and such Medtronic employees to the extent
necessary to permit the disclosures and consulting contemplated under Section 2.6(c). In addition, Medtronic acknowledges (a) Licensee intends to hire M. Jacqueline Eastwood, a former Medtronic employee as its president, and Medtronic has
waived any non-compete and confidentiality obligations of Ms. Eastwood to the extent necessary to permit such employment, and (b) Licensee may have discussions with [*], a former Medtronic employee, concerning the Subject Technology and
Medtronic hereby waives any confidentiality obligations of [*] to the extent necessary to permit such discussions. 
 2.7. Right of
Notification. If Medtronic, at any time during the one (1) year period commencing on the date of execution of this Agreement, decides to license to [*] any other [*] technologies (including without limitation, any [*] technology for [*]),
it shall so notify the CEO or President of Licensee in writing or orally, prior to entering into any license agreement. As used in this Section 2.7, the term “[*] technology” shall mean any technology for the manufacture, use or sale
of any product or device that [*]. 
 ARTICLE 3 
 Royalties and Reports 
 3.1. License Fee. On the date of execution of this Agreement by the
parties, Licensee shall immediately pay to Medtronic a payment of Seven Hundred Fifty Thousand Dollars ($750,000) by wire transfer of such amount in immediately available funds to an account designated by Medtronic. Upon the successful completion by
Licensee of a second round of equity financing or debt financing which is convertible to equity after the Effective Date, Licensee shall immediately pay to Medtronic a payment of One Million Dollars ($1,000,000) by wire transfer of such amount in
immediately available funds to an account designated by Medtronic. On the date of execution of this Agreement, Medtronic will also receive 993,756 shares of the common stock, $.01 par value, of Licensee (“Common Stock”) and a Warrant,
dated as of the Effective Date, to purchase up to 124,222 additional shares of Common Stock. 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 6 

 Medtronic shall have the right to maintain its proportionate ownership of Licensee by investing in future financing
rounds along with other investors at that time pursuant to the terms of the Investors’ Rights Agreement by and among Licensee, Medtronic and certain investors, dated as of the Effective Date (the “Investors’ Rights Agreement”).

 3.2. Royalties on Net Sales by Licensee. Subject to the terms of this Agreement, Licensee shall pay to Medtronic a royalty (the
“Royalty” or “Royalties”) equal to a percentage of Net Sales of Licensed Products, as follows: 
 (a) The first [*]
Dollars ($[*]) of cumulative Net Sales of Licensed Products by Licensee and by any sublicensee, Affiliate and third party permitted under Section 2.2 after the Effective Date shall bear a royalty of seven and half percent (7.5%). 
 (b) The next [*] Dollars ($[*]) of cumulative Net Sales of Licensed Products by Licensee and by any sublicensee, Affiliate and third party permitted
under Section 2.2 shall bear a royalty of [*] percent ([*]%). 
 (c) The next [*] Dollars ($[*]) of cumulative Net Sales of Licensed
Products by Licensee and by any sublicensee, Affiliate and third party permitted under Section 2.2 shall bear a royalty of [*] percent ([*]%). 
 (d) Net Sales of Licensed Products by Licensee in excess of a cumulative [*] Dollars ($[*]) of Net Sales of Licensed Products by Licensee and by any sublicensee, Affiliate and third party permitted under Section 2.2 after the Effective
Date shall bear a royalty of two percent (2%). 
 3.3. Minimum Royalties. Licensee agrees to pay to Medtronic a minimum annual royalty
as set forth below. Licensee’s obligation to pay minimum annual royalties shall commence on January 1, 2003. Annual minimum royalties for each calendar year commencing on January 1, 2003 shall be (i) $[*] for 2003 and 2004, and
(ii) $300,000 for 2005 and each year thereafter. If Royalties on Net Sales of Licensed Products during the applicable calendar year are less than the applicable minimum annual royalty, the Licensee shall pay Medtronic the difference between
such Royalty and the minimum annual royalty. Such annual amounts shall be payable within forty-five (45) days after the end of the applicable calendar year. 
 3.4. Reports and Payments. Within forty-five (45) days after the end of each Quarter, Licensee shall provide Medtronic with a written report indicating (i) the amount of Net Sales of Licensed Products
by Licensee and by any sublicensee, Affiliate or third party permitted under Section 2.2 during such Quarter, and (ii) the amount of the Royalties due for such Quarter. Simultaneously with making such report, Licensee shall pay to
Medtronic the amount of royalties then due. 
 3.5. Records. Licensee agrees to keep and cause sublicensees, Affiliates and third
parties permitted under Section 2.2 to keep accurate written records sufficient in detail to enable Medtronic to verify the information contained in the reports described in Section 3.3. Such records for a particular Quarter shall be
retained by Licensee and such sublicensees, Affiliates and third parties for a period of not less than four years after the end of such Quarter. 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 7 

 3.6. Audit of Records. Upon reasonable notice and during regular business hours Licensee and any
sublicensee, Affiliate and third party permitted under Section 2.2 shall from time to time (but no more frequently than once annually) make available the records referred to in Section 3.4 for audit by an independent nationally recognized
accounting firm selected by Medtronic to verify the accuracy of the reports provided to Medtronic. Such representatives shall execute a suitable confidentiality agreement reasonably acceptable to Licensee or such sublicensee, Affiliate or third
party prior to conducting such audit. Such representatives may disclose to Medtronic only their conclusions regarding the accuracy and completeness of the reports described in Section 3.3 and the records related thereto, and shall not disclose
confidential business information of Licensee or such sublicensee, Affiliate or third party to Medtronic without the prior written consent of Licensee or such sublicensee, Affiliate or third party. Such audits shall be at Medtronic’s cost and
expense; provided that if any such audit reveals underpayment of Royalties by five percent (5%) or more for any Quarter, then Licensee shall reimburse Medtronic for the fees and expenses of Medtronic’s independent auditors incurred by
Medtronic in connection with such audit. 
 ARTICLE 4 
 Additional Obligations 
 4.1. Restrictions on Use. Licensee will use all reasonable efforts to
ensure that all Licensed Products designed, developed, manufactured or sold by Licensee or its Affiliates, sublicensees or third parties with the use of any Subject Technology are not used outside of the Field of Use. 
 4.2. Confidentiality. The parties acknowledge that the patent applications listed in Exhibit A hereto, the inventions claimed therein, and all
trade secrets and know-how included within the Subject Technology constitute “Confidential Information” of Medtronic, subject to the exceptions set forth in Section 1.3. Each party agrees not to disclose or use any of the other
party’s Confidential Information except as expressly permitted in connection with the exercise of its rights hereunder. Each party shall not disclose the other party’s Confidential Information to any employee or consultant unless such
employee or consultant is obligated under a confidentiality agreement to maintain such other party’s Confidential Information in strict confidence, and not to use such information other than, in accordance with the terms of this Agreement. Each
party agrees to hold the other party’s Confidential Information in strict confidence and treat it with not less than the same degree of care to avoid disclosure as such party employs with respect to its own information of like importance.

 4.3. Infringement by Third Party. Licensee shall promptly notify Medtronic and Medtronic shall promptly notify Licensee in writing
if Medtronic or Licensee knows or has reason to believe that the rights of Medtronic or Licensee relating to the Subject Technology are being infringed by a third party. 
 4.4. Covenant Regarding Claims. Licensee agrees, for itself and for its Affiliates, sublicensees, successors, assigns, and other parties claiming any title or license to any Subject Technology, not to sue or
otherwise assert any claim against Medtronic, or any of 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 8 

 its Affiliates, successors, assigns, customers, vendors, or others in contractual privity with any of the foregoing, by
reason of or with respect to the use of such Subject Technology disclosed to Licensee as of the Effective Date or thereafter; provided, however, the foregoing shall not prevent any action on the part of Licensee, its Affiliates, successors or
assigns brought to enforce Licensee’s rights and Medtronic’s obligations under this Agreement. 
 4.5. Opinion of Counsel.
Licensee will deliver to Medtronic contemporaneously with the execution of this Agreement an opinion of Dorsey & Whitney, LLP, counsel to Licensee, substantially in the form as that provided to certain investors under Section 4.8 of
the Series A Convertible Preferred Stock Purchase Agreement between Licensee and such investors and executed contemporaneously with this Agreement (the “Investor Agreement”). 
 ARTICLE 5 
 Intellectual Property 
 5.1. No Representation or Warranty. EXCEPT AS PROVIDED IN ARTICLE 6, MEDTRONIC MAKES NO WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE
SUBJECT TECHNOLOGY OR ANY LICENSED PRODUCTS, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, PATENTABILITY, PATENT VALIDITY, NON-INFRINGEMENT, OR WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF
TRADE. 
 5.2. Control of Subject Technology. 
 (a) Medtronic shall have the sole and exclusive right, in Medtronic’s absolute discretion and at its sole expense, to prosecute any alleged infringement, misappropriation or misuse of the Subject Technology:
(i) outside the Field of Use, and shall retain all proceeds from prosecution up to the amount of any expenses of prosecution and investigation as well as retain all proceeds from prosecution in excess of expenses of prosecution and
investigation, and (ii) in the Field of Use, and shall retain all proceeds from prosecution up to the amount of any expenses of prosecution and investigation and shall retain fifty percent (50%) of all proceeds from such prosecution in
excess of expenses of prosecution and investigation and shall pay the balance to the Licensee. If Medtronic decides at any time not to commence or continue to prosecute any alleged infringement, misappropriation or misuse of the Subject Technology
in the Field of Use, it shall so notify Licensee in writing, and Licensee shall have the right, in its absolute discretion, to commence or continue such prosecution. If Licensee chooses to commence or continue such prosecution, Licensee shall
either: (i) fully fund such prosecution at its sole expense and shall retain all proceeds from prosecution up to the amount of any expenses of prosecution and investigation as well as retain seventy five percent (75%) of all proceeds from
prosecution in excess of expenses of prosecution and investigation and shall pay the balance to Medtronic, or (ii) fully fund such prosecution provided, however, that Licensee may supplement such funding by offsetting any prosecution expenses
against current Royalties due Medtronic under Section 3.2 and shall pay fifty (50%) of all proceeds from such prosecution to Medtronic without deducting from such proceeds any expenses of prosecution and investigation. If Licensee chooses
to commence or continue such prosecution, Licensee shall simultaneously 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 9 

 determine whether it wishes to choose option (i) or (ii) above and shall promptly notify Medtronic of its
choice, which shall be binding upon Licensee. If Licensee chooses option (ii) above, it shall offset prosecution expenses against Royalties on a calendar year basis. To the extent that Royalties in a calendar year exceed prosecution expenses in
the same calendar year, Licensee shall offset such expenses and pay the balance of the Royalties to Medtronic. In no event shall expenses offset by Licensee exceed the actual Royalties due Medtronic. At the request of the party prosecuting a suit,
the other party shall cooperate with the party prosecuting the suit in any such legal action either party may prosecute or defend under this Section 5.2(a). 
 (b) Medtronic shall have the sole right to [*] of any [*] included within the [*], any [*], or any other [*] related to [*] included within the [*]. The parties agree to consult in good faith regarding the foreign
countries in which [*]. Medtronic shall furnish Licensee with copies of any [*] concerning the [*] sufficiently in advance of [*] so as to give Licensee reasonable opportunity to review and comment. Medtronic shall also furnish to Licensee copies of
all substantive communications to and from [*] regarding [*] concerning the [*] within a reasonable time prior to filing such communication or promptly following receipt thereof, as the case may be, so as to give Licensee reasonable opportunity to
review and comment. Medtronic shall supply Licensee with a copy of each [*], together with notice of its [*]. 
 5.3. Indemnification.

 (a) Licensee shall indemnify, defend and hold harmless Medtronic, its Affiliates and Medtronic’s and its Affiliates’ respective
officers, directors, shareholders, employees and agents (collectively, all such indemnitees are referred to in this Section 5.3(a) as “Medtronic Indemnitees”) against and in respect of any and all claims, demands, losses, obligations,
liabilities, damages (and including without limitation compensatory and punitive damages), deficiencies, Actions, settlements, judgments, costs and expenses which the Medtronic Indemnitees may incur or suffer or with which it may be faced (including
reasonable costs and legal fees incident thereto or in seeking indemnification therefor) arising out of or based upon (i) any Product Liability Claims resulting from development, manufacture, use, or sale of any Licensed Product by Licensee or
any sublicensee, Affiliate or third party permitted under Section 2.2, or (ii) any breach of this Agreement by Licensee or any sublicensee, Affiliate or third party permitted under Section 2.2. 
 (b) Medtronic shall indemnify and hold harmless Licensee and its Affiliates and their respective officers, directors, shareholders, employees and agents
(collectively, all such indemnitees are referred to in this Section 5.3(b) as “Licensee Indemnitees”) against and in respect of any and all demands, losses, obligations, liabilities, damages (and including without limitation
compensatory and punitive damages), deficiencies, Actions, settlements, judgments, costs and expenses which the Licensee Indemnitees may incur or suffer or with which it may be faced (including reasonable costs and legal fees incident thereto or in
seeking indemnification therefor) arising out of or based upon any breach of this Agreement by Medtronic. 
 5.4. Limitation on
Liability. In no event shall Medtronic’s liability under this Agreement exceed [*] Dollars ($[*]) regardless of the form or basis of the action or claim, except with respect to (i) the grant by Medtronic of any license under the
Subject Technology to make, have made, use or sell Wet Electrode Products in the Field of Use that are Licensed Products, in the Territory, to any third 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 10 

 party; (ii) the manufacture, use or sale by Medtronic of Wet Electrode Products in the Field of Use that are
Licensed Products, in the Territory; (iii) breach by Medtronic of its obligations of non-disclosure and non-use under Section 4.2, or (iv) breach by Medtronic of its representations and warranties under Article 6. 
 5.5. Licensee Regulatory Interaction Rights. Notwithstanding Section 5.2 above, interaction with the regulatory agencies in any country,
including, without limitation the FDA, concerning Wet Electrode Products of Licensee in the Field of Use shall be exclusively conducted by Licensee and Licensee shall be the official company sponsor. Subject to Section 5.3(a) hereof, Licensee
shall have complete authority to act as Licensee, in its sole discretion, deems appropriate with respect to any such regulatory matter. 
 5.6. Licensee Marketing Rights. Nothing herein shall prevent or limit Licensee from setting its own prices for Licensed Products or determining Licensee’s marketing policies and practices in its sole discretion. 
 5.7. Trademark. Nothing in this Agreement shall be deemed to grant to Licensee any right to use the trademark “Medtronic”, the Medtronic
corporate logo, or any other trademark owned by Medtronic or its Affiliates. 
 ARTICLE 6 
 Representations & Warranties 
 6.1. Organization. Each party represents and warrants to the other party that such party is a corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its incorporation. 
 6.2. Authorization of Transaction. Each party represents and warrants to the other party that it has full power and authority (including full
corporate power and authority) to execute and deliver this Agreement and to perform its obligations hereunder. All necessary corporate proceedings (including any necessary approval by the board of directors) have been taken by such party to duly
authorize the execution, delivery, and performance of this Agreement by such party. This Agreement constitutes the valid and legally binding obligation of such party, enforceable against such party in accordance with its terms and conditions.

 6.3. No Conflicts. Medtronic represents and warrants to Licensee that it has not entered into any inconsistent prior obligations
concerning the Subject Technology that would prevent Licensee from exercising the rights being licensed to it hereunder. 
 6.4. No
Claims. Medtronic represents and warrants to it has not received written notification from a third party that the manufacture, use, importation or sale of the License Products under the license granted herein under the Subject Technology will
infringe any patents, copyrights, trade secrets or any other intellectual property rights of any third parties. 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 11 

 ARTICLE 7 
 Miscellaneous 
 7.1. Assignment. Either party may assign or otherwise transfer its rights and
obligations under this Agreement to any successor in interest (by merger, share exchange, combination or consolidation of any type, operation of Law, purchase or otherwise), provided that such assignee or successor agrees to be bound by the terms
hereof, and provided further that in the event of such an assignment by Licensee, Licensee’s consulting agreement with [*], if any, pursuant to Section 2.6 and Licensee’s right of notice pursuant to Section 2.7 shall terminate
effective upon such transfer and assignment. Except as set forth above, Licensee may not assign or otherwise transfer its rights and obligations under this Agreement and any attempt to so assign or otherwise transfer its rights and obligations under
this Agreement shall represent a breach of the Agreement. 
 7.2. Entire Agreement. This Agreement, together with the Exhibits hereto,
the Investor Agreement and the Investors’ Rights Agreement, constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all previous proposals or agreements, oral or written, and all negotiations,
conversations or discussions heretofore had between the parties related to the subject matter of this Agreement. 
 7.3. Survival.
Articles 4 and 7 and Section 5.3 shall survive termination or expiration of this Agreement for any reason and continue thereafter in full force and effect. 
 7.4. Waiver, Discharge, etc. This Agreement may not be released, discharged, abandoned, changed or modified in any manner, except by an instrument in writing signed on behalf of each of the parties to this
Agreement by their duly authorized representatives. The failure of either party to enforce at any time any of the provisions of this Agreement shall in no way be construed to be a waiver of any such provision, nor in any way to affect the validity
of this Agreement or any part of it or the right of either party after any such failure to enforce each and every such provision. No waiver of any breach of this Agreement shall be held to be a waiver of any other or subsequent breach. 

7.5. Execution in Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same
agreement, and shall become a binding agreement when one or more counterparts have been signed by each party and delivered to the other party. 
 7.6. Titles and Headings: Construction. The titles and headings to Sections herein are inserted for the convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.
This Agreement shall be construed without regard to any presumption or other rule requiring construction hereof against the party causing this Agreement to be drafted. 
 7.7. Benefit. Nothing in this Agreement, expressed or implied, is intended to confer on any person other than the parties to this Agreement or their respective permitted successors or assigns, any rights,
remedies, obligations or liabilities under or by reason of this Agreement. 
 7.8. Notices. All notices or other communications to a
party required or permitted hereunder shall be in writing and shall be delivered personally or by telecopy (receipt confirmed) to such party (or, in the case of an entity, to an executive officer of such party) 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 12 

 or shall be given by certified mail, postage prepaid with return receipt requested, addressed as follows: 
 if to Licensee, to: 
 Virtuel Medical Devices, Inc.

 800 LaSalle Avenue, Suite 2250 
 Minneapolis, Minnesota 55402 
 Attention:       President 

	 	  	Facsimile number: (612) 607-2801 

 and if to Medtronic, to:

 Medtronic, Inc. 
 Corporate
Center 
 7000 Central Avenue N.E. 
 Minneapolis, Minnesota 55432 
 with separate copies thereof addressed to: 
  

			
	Attention:	    	General Counsel
		    	Facsimile number: (612) 572-5459
		
	Attention:	    	Vice President and Chief Development Officer
		    	Facsimile number: (612) 572-5404

 Licensee or Medtronic may change their respective above-specified recipient and/or mailing address by notice to
the other party given in the manner herein prescribed. All notices shall be deemed given on the day when actually delivered as provided above (if delivered personally or by telecopy) or on the day shown on the return receipt (if delivered by mail).

 7.9. Severability. If any provision of this Agreement is held invalid by a court of competent jurisdiction, the remaining
provisions shall nonetheless be enforceable according to their terms. Further, if any provision is held to be overbroad as written, such provision shall be deemed amended to narrow its application to the extent necessary to make the provision
enforceable according to applicable Law and shall be enforced as amended. 
 7.10. [*]. If requested by Medtronic, Licensee shall cause all
Licensed Products manufactured or sold under this license in the United States by it [*]. 
 7.11. Governing Law. This Agreement shall
be construed in accordance with Minnesota law, excluding its choice of law provisions. 
 [Signature Page Follows] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 13 

 IN WITNESS WHEREOF, each of the parties has caused this License Agreement to be executed in the manner
appropriate to each, effective as of the date first above written. 
  

			
	VIRTUEL MEDICAL DEVICES, INC.
		
	By:	 	 /s/ Jay Schmelter Aug 9, 1999

	Its:	 	President
	
	MEDTRONIC, INC.
		
	By:	 	 /s/ Michael D. Ellwein

	Its:	 	Vice President

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 Exhibit A 
 Subject Technology 
  

									
	Issued U.S. Patents
					
	 Medtronic Docket No
	 	 Title
	 	 Serial No.
	 	 Filing Date
	 	 Patent No.

	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	
	Pending U.S. Utility Patent Applications
					
	 Medtronic Docket No.
	 	 Title
	 	 Serial No.
	 	 Filing Date
	 	 
	[*]	 	[*]	 	[*]	 	[*]	 	
	[*]	 	[*]	 	[*]	 	[*]	 	
	[*]	 	[*]	 	[*]	 	[*]	 	
	[*]	 	[*]	 	[*]	 	[*]	 	

  

	*	[*] 

  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

							
	Pending U.S. Provisional Patent Applications
				
	 Medtronic Docket No.
	 	 Title
	 	 Serial No.
	 	 Filing Date

	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]

  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 Exhibit B 
 Know-How Transfer 
 Pursuant to Section 2.6, Medtronic shall provide Licensee with the
following, subject to the withholding of material which is subject to an attorney-client privilege, whether in written or electronic format, relating specifically to Wet Electrode Products and Wet Electrode Generators: 
 [*] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 AMENDMENT NO. 1 TO LICENSE AGREEMENT 
 This Amendment No. 1 is an amendment to the License Agreement (the “License Agreement”) by and between TissueLink Medical, Inc., formerly
named Virtuel Medical Devices, Inc. (“Licensee”), and Medtronic, Inc. (“Medtronic”) dated as of August 9, 1999. This Amendment No. 1 is dated as of June 18, 2002. All capitalized terms not defined in this Amendment
No. 1 shall have the meanings set forth in the License Agreement. 
 The parties hereby agree that the License Agreement is amended as
follows: 
 ARTICLE 8 Name of Licensee. All references to Virtuel Medical Devices, Inc. shall be deemed to refer to the Licensee,
TissueLink Medical, Inc. 
 ARTICLE 9 Field of Use. Section 1.5 of the License Agreement is hereby amended as follows:

  

	 	(a)	The phrase “the vertebrae, spinal column and brain and the head and neck and [*] and [*] and [*] thereof” in clause (ii) of the first sentence shall be replaced with
the phrase “the brain and the head and neck and [*] and [*] and [*] thereof (other than those of the [*] portion of the [*]).” 

  

	 	(b)	The following sentence shall be added after the second sentence: ‘[*] Applications’ shall mean any medical applications in [*] (including, but not limited to, [*])
relating to the vertebrae and [*].” 

 ARTICLE 10 Wet Electrode Products. Section 1.14 shall be amended to
read in its entirety as follows: 
 ‘Wet Electrode Products’ shall mean medical products, devices, or systems that employ an
electrode to deliver radio frequency energy and an electrically conductive fluid between the electrode and living tissue to apply radio frequency energy in medical applications in the Field of Use. Wet Electrode Products specifically exclude any
interstitial needle or intraluminal wire devices or products.” 
 ARTICLE 11 License Grant. Section 2.1 shall be amended to
read in its entirety as follows: 
 “Subject to the terms and conditions hereof, Medtronic hereby grants to Licensee (a) a
royalty-bearing and exclusive license under the Subject Technology, with the right to grant sublicenses subject to the terms of Section 2.2 hereof, to make, have made, use and sell Wet Electrode Products in the Field of Use (other than Spinal
Applications) that are Licensed Products throughout the Territory, (b) a royalty-bearing and co-exclusive license, subject to the rights retained by Medtronic and described in the last sentence of this Section 2.1, under the Subject
Technology, with no 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 18 

 right to grant sublicenses, to make, have made, use and sell Wet Electrode Products for Spinal
Applications in the Field of Use that are Licensed Products throughout the Territory, and (c) a royalty-bearing and non-exclusive license under the Subject Technology, with the right to grant sublicenses subject to the terms of Section 2.2
hereof, to make, have made, use and sell Wet Electrode Generators in the Field of Use that are Licensed Products throughout the Territory. Medtronic has no right to grant licenses or sublicenses to the Subject Technology to make, have made, use or
sell Wet Electrode Products for Spinal Applications in the Field of Use that are Licensed Products in the Territory; provided, however, that Medtronic may grant one or more Permitted Spinal Product Licenses (as defined in
Section 3.2) on or after June 18, 2003; provided, further, however, that, subject to any confidentiality limitations applicable to Medtronic in connection with such grant, Medtronic shall give Licensee notice of the granting
of any Permitted Spinal Product License within fifteen (15) days of the effective date of such grant, (such notice to identify the licensee or sublicensee and the litigation or dispute relating to such grant and to describe the scope of the
license in reasonable detail), and shall provide Licensee with additional information upon reasonable request in order to enable Licensee to verify that such license or sublicense was granted in accordance with the terms of this Agreement.”

 ARTICLE 12 Sublicensing and Distribution. Section 2.2 shall be amended by adding the following phrase before the first word of
the first sentence: “Except as otherwise provided in Section 2.1, ....” 
 ARTICLE 13 Royalty on Spinal Licensed
Products. Section 3.2 shall be amended as follows: 
  

	 	13.1.	All references to “Net Sales of Licensed Products” shall be replaced with the phrase, “Net Sales of Licensed Products excluding Spinal Licensed Products.”

  

	 	13.2.	The following paragraph shall be added after the last sentence of Section 3.2: 

 “For purposes of this Agreement, ‘Spinal Licensed Products’ shall mean Licensed Products marketed for Spinal Applications. For purposes of this Agreement, ‘Permitted Spinal Product
License’ shall mean a license or sublicense to make, have made, use and sell Wet Electrode Products for Spinal Applications in the Field of Use that are Licensed Products in the Territory granted by Medtronic to a third party that is not an
Affiliate of Medtronic as is necessary or appropriate (as determined by Medtronic in its sole discretion) solely for the 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 19 

 purpose of settling litigation between Medtronic and the third party relating to Medtronic’s
intellectual property rights or settling another bona fide dispute between Medtronic and the third party relating to Medtronic’s intellectual property rights. Subject to the terms of this Agreement, Licensee shall pay to Medtronic a royalty
equal to a percentage of Net Sales of Spinal Licensed Products as follows: 
 (e) The first [*] Dollars ($[*]) of cumulative
Net Sales of Spinal Licensed Products by Licensee and by any sublicensee, Affiliate and third party permitted under Section 2.2 after the Effective Date shall bear a royalty of seven and half percent (7.5%). 
 (f) The next [*] Dollars ($[*]) of cumulative Net Sales of Spinal Licensed Products by Licensee and by any sublicensee, Affiliate and
third party permitted under Section 2.2 shall bear a royalty of [*] percent ([*]%). 
 (g) The next [*] Dollars ($[*])
of cumulative Net Sales of Spinal Licensed Products by Licensee and by any sublicensee, Affiliate and third party permitted under Section 2.2 shall bear a royalty of [*] percent ([*]%). 
 (h) Net Sales of Spinal Licensed Products by Licensee in excess of a cumulative [*] Dollars ($[*]) of Net Sales of Spinal Licensed
Products by Licensee and by any sublicensee, Affiliate and third party permitted under Section 2.2 after the Effective Date shall bear a royalty of two percent (2%). 
 (i) Notwithstanding the foregoing, in the event Medtronic grants a Permitted Spinal Product License, then (A) the provisions of
clauses (e) - (h) of this Section 3.2 shall no longer apply and (B) Net Sales of Spinal Licensed Products on and after the effective date of such Permitted Spinal Product License by Licensee and by any sublicensee, Affiliate and
third party permitted under Section 2.2 shall bear a royalty of [*] percent ([*]%).” 
 ARTICLE 14 Minimum Royalties.
Section 3.3 shall be amended by replacing the phrase “Royalties on Net Sales of Licensed Products” in the fourth sentence with the phrase “Royalties on Net Sales of Licensed Products excluding Spinal Licensed Products.”

 ARTICLE 15 Intellectual Property. The following subparagraph shall be added to Section 5.2 and designated as subsection (c):

 “(c) In the event that Medtronic (i) [*] included within the Subject Technology which relates to the Field of Use, Licensee
shall have the right to exercise complete control, at Licensee’s expense and upon written notice to 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 20 

 Medtronic, over such [*]. Medtronic shall copy Licensee on all correspondence with respect to
Medtronic’s [*] included within the Subject Technology such that Licensee has the reasonable opportunity to take such action as may be necessary to [*] in the event Medtronic [*]. For purposes of this Section 5.2(c), [*] shall include a
reference to [*].” 
 ARTICLE 16 Notices. The following address replaces the address listed for Licensee in Section 7.8 of
the License Agreement: 
 TissueLink Medical, Inc. 
 One Washington Center 
 Suite 400 
 Dover, NH 03820 
 Attn: Chief Executive Officer 
 Facsimile number: (603) 742-1488 
 ARTICLE 17 Miscellaneous. Except as otherwise expressly
amended by this Amendment, the terms and conditions of the License Agreement shall remain in full force and effect. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 
 [Signature pages follow.] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 21 

 IN WITNESS WHEREOF, the parties to this Amendment have executed this Amendment No. 1 to the License
Agreement as of the date first written above. 
  

			
	MEDTRONIC, INC.
		
	By:	 	 /s/ Michael D. Ellwein

	Its:	 	VP & CDO
	
	TISSUELINK MEDICAL, INC.
		
	By:	 	 /s/ M. Jacqueline Eastwood

	Its:	 	Pres. & CEO

  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 22 

 AMENDMENT NO. 2 
 TO 
 LICENSE AGREEMENT 
 THIS AMENDMENT NO. 2 TO LICENSE AGREEMENT (the “Amendment”) is entered into as of March 1, 2004 (the “Effective Date”), by and
between TissueLink Medical, Inc. (“Licensee”) and Medtronic, Inc. and it amends that certain License Agreement dated as of August 9, 1999 between the parties as amended by Amendment No. 1 to License Agreement dated June 18,
2002 (the “License Agreement”). 
 The parties hereby agree that the License Agreement is amended as follows: 
 1. Minimum Royalties. The last sentence of Section 3.3 of the License Agreement is deleted and replaced with the following: 
 “Within forty-five (45) days after the end of calendar years 2004, 2005 and 2006, Licensee shall: (i) execute and deliver to Medtronic a
promissory note on the terms and in the form of the promissory note set forth in Exhibit A (the “Form Note”) in the principal amount of the annual amount due Medtronic pursuant to this Section 3.3 with respect to such calendar year;
and (ii) execute and deliver to Medtronic a warrant on the terms and in the form set forth in Exhibit B (the “Form Warrant”) entitling Medtronic to purchase that number of shares equal to: (A) such annual amount due Medtronic
pursuant to this Section 3.3 with respect to such calendar year multiplied by .05; divided by (B) the Exercise Price (as defined in the Form Warrant). Any annual amount due Medtronic pursuant to this Section 3.3
applicable to periods from and after January 1, 2007, shall be payable within forty-five (45) days after the end of the applicable calendar year.” 
 2. Royalty Payments. The last sentence of Section 3.4 of the License Agreement is deleted and replaced with the following: 
 “Simultaneously with delivery to Medtronic of a report for any Quarter from January 1, 2004 through December 31, 2006, Licensee shall: (i) execute and deliver to Medtronic a promissory note in
favor of Medtronic on the terms and in the form of the Form Note in the principal amount of the quarterly Royalty due Medtronic for such Quarter; and (ii) execute and deliver to Medtronic a warrant on the terms and in the form of the Form
Warrant for that number of shares equal to (A) the amount of the Royalty due Medtronic for such Quarter multiplied by .05; divided by (B) the Exercise Price (as defined in the Form Warrant). For Quarters from and after
January 1, 2007, simultaneously with making any report pursuant to this Section 3.4, Licensee shall pay to Medtronic the amount of royalties then due.” 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 23 

 3. No Conflicts. A new Section 3.7 shall be added to the License Agreement and shall read in
its entirety as follows: 
 “Licensee represents and warrants to Medtronic that the execution, delivery and performance by Licensee of
the promissory notes and warrants contemplated by Sections 3.3 and 3.4 will not: (a) result in a breach or violation of, or default under, any material contract to which Licensee is a party or by which it is bound (including without limitation
the Credit Agreement with Brown Brothers Harriman & Co. dated as of September 3, 2002, as amended, and related credit documents and the Convertible Promissory Note issued to Century Medical Inc. dated April 29, 2002, and the
related Distribution Agreement with Century Medical Inc.); (b) result in the creation or imposition of a lien or other encumbrance upon, or the forfeiture of, any material asset or assets of Licensee; or (c) result in a breach or violation
of, or default under, the certificate of incorporation or by-laws of Licensee.” 
 3. Miscellaneous. Except as otherwise
expressly amended by the Amendment No. 2, the terms of the License Agreement shall remain in full force and effect. This Amendment may be executed in any number of counterparts, each of which shall be deemed as original, but all of which
together shall constitute one and the instrument. 
 [Signature page follows.] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 24 

 IN WITNESS WHEREOF, each of the parties has caused this Amendment No. 2 to License Agreement to be
executed in the manner appropriate for each, and to be dated as of the date first above-written. 
  

			
	TISSUELINK MEDICAL, INC.
		
	By:	 	 /s/ Joseph Army / /s/ M. Jacqueline Eastwood

	Name:	 	Joseph Army / M. Jacqueline Eastwood
	Title:	 	VP & CFO / Pres. & CEO
	
	MEDTRONIC, INC.
		
	By:	 	 /s/ Michael D. Ellwein

	Name:	 	Michael D. Ellwein
	Title:	 	VP & CDO

  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 Execution Copy 
  
 EXHIBIT A 
 FORM PROMISSORY NOTE 
  

					
	$                    	 		 	Minneapolis Minnesota

                         , 2004 
 FOR VALUE RECEIVED, the undersigned, TissueLink Medical, Inc., a Delaware corporation (“Maker”), hereby promises to pay to the order of Medtronic, Inc., (“Payee”), at Payee’s principal place
of business, or such other place as Payee under this Promissory Note may from time to time designate in writing, in lawful money of the United States of America the principal sum of
                         and     /100 Dollars
($                    ) [Amount to equal amount that would otherwise be paid as royalty pursuant to License Agreement for
applicable time period through December 31, 2006]. 
 The principal of this Note and accrued interest shall be due and payable
in full on March 31, 2007. Maker shall pay interest on the outstanding principal amount of this Note from the date hereof until payment in full hereof at an annual rate equal to ten percent (10%). Notwithstanding the foregoing, from and after
the occurrence of any Event of Default (as defined below) and during the continuance thereof, the interest rate shall be equal to eighteen percent (18%) per annum. 
 Until payment in full of the principal amount set forth above, interest on the outstanding principal amount hereof shall be payable quarterly, commencing [first day of next calendar quarter] and shall be
payable the first day of each quarter thereafter. Interest as aforesaid shall be charged for the actual number of days elapsed over a year consisting of three hundred sixty-five (365) days on the actual daily outstanding balance hereof.

 Maker may prepay this Note in whole or in part at any time without premium or penalty. Any partial prepayment of this Note shall be
applied first to any unpaid interest on this Note. 
 Upon the occurrence of an Event of Default and the acceleration of this Note as
provided below, this Note shall be immediately due and payable. The occurrence of any one or more of the following events shall constitute an “Event of Default”: 
 (a) Maker shall fail to make when due, whether by acceleration or otherwise, any payment of principal of, or interest on, this Note; or

 (b) Maker shall materially breach any agreement, covenant, condition, provision or term contained in the License Agreement
or the documents relating thereto; or 
 (c) If (i) Maker shall (1) be or become insolvent, or (2) apply for or
consent to the appointment of, or the taking of possession by, a receiver, custodian, trustee, liquidator or the like of the person or of all or a substantial part of the person’s property, or (3) commence a voluntary case under any
bankruptcy, insolvency, reorganization, arrangement, readjustment of debt, dissolution, liquidation or similar proceeding under the laws of any jurisdiction, or (4) file a petition seeking to take 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 26 

 Execution Copy 
  
 advantage of any other law relating to bankruptcy, insolvency, reorganization, winding up or composition or adjustment of
debts, or (5) admit in writing its inability to pay its debts as they mature, or (6) make an assignment for the benefit of its creditors; or (ii) a proceeding or case shall be commenced, without the application or consent of Maker,
and which is not dismissed within 30 days after such commencement, in any court of competent jurisdiction, seeking (1) the liquidation, reorganization, dissolution, winding up or the composition or adjustment of debts of Maker, (2) the
appointment of a trustee, receiver, custodian or liquidator or the like of the person or of all or any substantial part of Maker’s property, or (3) similar relief in respect of Maker under any law relating to bankruptcy, insolvency,
reorganization, winding up or composition or adjustment of debts); or 
 (d) The maturity of any indebtedness (other than
indebtedness under this Note and whether owed to the Payee or to others) of Maker shall be accelerated, or Maker shall fail to pay any such indebtedness when due or, in the case of such indebtedness payable on demand, when demanded, or any event
shall occur or condition shall exist and shall continue for more than the period of grace, if any, applicable thereto and shall have the effect of causing or permitting (any required notice having been given and grace period having expired) the
holder of any such indebtedness in such aggregate amount or any trustee or other person acting on behalf of such holder to cause, such indebtedness to become due prior to its stated maturity or to realize upon any collateral given as security
therefor; or 
 (e) Maker shall fail to pay, withhold, collect or remit any material tax or tax deficiency when assessed or
due or notice of any state or federal tax lien shall be filed or issued. 
 If (a) any Event of Default described in paragraph
(c) above shall occur, the outstanding unpaid principal balance of this Note and the accrued interest thereon shall automatically become immediately due and payable; or (b) any other Event of Default shall occur and be continuing and such
Event of Default is not cured by Maker within ten (10) days after written notice from Payee, then Payee may declare that the outstanding unpaid principal balance of this Note and the accrued and unpaid interest thereon to be immediately due and
payable, whereupon this Note, all accrued and unpaid interest thereon and all such other obligations shall immediately become due and payable, in each case without further demand or notice of any kind, all of which are hereby expressly waived,
anything in this Note to the contrary notwithstanding. In addition, upon any Event of Default and so long as such Event of Default continues, Payee may exercise all rights and remedies under any other instrument, document or agreement between Maker
and Payee and enforce all rights and remedies under any applicable law. 
 The indebtedness evidenced by this Note is hereby expressly
subordinated and subject and junior in right of payment, to the extent and in the manner hereinafter set forth below in this paragraph, to the prior payment in full of all Senior Indebtedness (as defined below in this paragraph): 
 As used in this Note, the term “Senior Indebtedness” shall mean the principal of and interest on all indebtedness, obligations and liabilities
of Maker under the Credit Agreement dated as of September 3, 2002, as amended on March 3, 2004, by and between Maker and Brown Brothers Harriman & Co. (the “BBH Credit Agreement”), the Security Agreement (as defined in
the BBH Credit Agreement) and the Notes (as defined in the BBH Credit Agreement). 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 27 

 Execution Copy 
  
 Subject to the provisions of subparagraph (d) below, no payment or distribution of any character, whether in cash, securities or other
property, shall be made on account of or applied to the principal of this Note prior to the earlier of: (i) the payment in full of the Senior Indebtedness or (ii) the stated maturity dates of the principal of and interest on the Senior
Indebtedness (the dates described in clauses (i) and (ii) are each referred to as the “Senior Indebtedness Maturity Date”). The foregoing limitation shall not be deemed to prohibit Maker from issuing warrants (or shares of
capital stock issuable upon exercise of such warrants) to Payee pursuant to the Amendment (as defined below). 
 If there should occur any
receivership, insolvency, assignment for the benefit of creditors, bankruptcy, reorganization or arrangements with creditors (whether or not pursuant to bankruptcy or other insolvency laws), sale of all or substantially all of the assets,
dissolution, liquidation or any other marshalling of the assets and liabilities of Maker, then prior to the Senior Indebtedness Maturity Date (i) no amount shall be paid by Maker in respect of the principal of this Note at the time outstanding,
unless and until the principal of and interest on the Senior Indebtedness then outstanding shall be paid in full, and (ii) no claim or proof of claim shall be filed with Maker by or on behalf of Payee that shall assert any right to receive any
payments in respect of the principal of this Note, except subject to the payment in full of the principal of and interest on all of the Senior Indebtedness then outstanding. 
 In the event that an Event of Default occurs and this Note is accelerated prior to the Senior Indebtedness Maturity Date, no payment shall be made in
respect of the principal of this Note unless, within thirty (30) days after the date Maker is required to give notice to the holder of Senior Indebtedness of the Event of Default (to the extent required by the terms of the Senior Indebtedness
instrument(s)), the maturity of such Senior Indebtedness shall not have been accelerated. If the maturity of such Senior Indebtedness is accelerated within such 30-day period, no payment shall be made in respect of the principal of this Note prior
to the payment in full of the Senior Indebtedness. 
 In the event any direct or indirect payment or distribution shall be received by the
holder of this Note in contravention of the provisions of subparagraph (b), (c) or (d) above, then such payment or distribution shall be held in trust for and shall be paid over or delivered to the holder of Senior Indebtedness, until all
Senior Indebtedness shall have been paid in full, after giving effect to any concurrent payment or distribution, or provision therefor, to the holder of Senior Indebtedness. 
 Nothing otherwise contained in this paragraph is intended to or shall impair, as among Maker, its creditors other than the holder of Senior Indebtedness,
and Payee, the obligations of Maker, which are, subject to the terms of this paragraph, absolute and unconditional, to pay the Note, as and when the same shall become due and payable in accordance with its terms, or to affect the relative rights of
Payee and creditors of Maker other than the holder of Senior Indebtedness, nor shall anything herein or therein prevent Payee from exercising all rights permitted it hereunder upon the acceleration of this Note, subject to the rights, if any, under
this paragraph of the holder of Senior Indebtedness in respect of cash, property or securities of Maker received upon the exercise of any such remedy. 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 28 

 Execution Copy 
  
 By its acceptance of this Note, Payee agrees to execute and deliver such documents as may be reasonably requested from time to time by Maker
or the holder of Senior Indebtedness in order to implement the foregoing provisions of this paragraph. 
 This Note is issued in connection
with, and subject to the terms and conditions of, that certain Amendment No. 2 to License Agreement dated March 1, 2004 (the “Amendment”), among Maker and Payee. Any transferee of this Note accepts it subject to the terms and
conditions of the Amendment. 
 This Note shall be interpreted and the rights and liabilities of the parties hereto determined in accordance
with the laws of the State of Minnesota. If any provision of this Note or the application thereof shall be held to be void or unenforceable by any court of competent jurisdiction, such defect shall not affect the remainder of this Note, which shall
continue in full force and effect. Maker agrees to reimburse the Payee upon demand for all reasonable expenses paid or incurred by Payee (including costs and fees and expenses of legal counsel) in connection with the collection and enforcement of
this Note. 
 Whenever in this Note reference is made to Payee or Maker, such reference shall be deemed to include, as applicable, a
reference to their respective successors and assigns. The provisions of this Note shall be binding upon Maker and its successors and assigns, and shall inure to the benefit of Payee and its successors and assigns. 
  

			
	TISSUELINK MEDICAL, INC.
		
	By:	 	  

	Its:	 	  

  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 29 

 Execution Copy 
  
 AMENDMENT NO. 3 
 TO 
 LICENSE AGREEMENT 
 THIS AMENDMENT NO. 3 TO LICENSE AGREEMENT (the “Amendment”) is entered into as of July 18, 2006 (the “Effective Date”), by and between TissueLink Medical, Inc. (“Licensee”) and
Medtronic, Inc. and it amends that certain License Agreement dated as of August 9, 1999 between the parties as amended by Amendment No. 1 to License Agreement dated June 18, 2002 and Amendment No. 2 to License Agreement dated
March 1, 2004 (the “License Agreement”). 
 The parties hereby agree that the License Agreement is amended as follows:

 1. Field of Use. Section 1.5 of the License Agreement is hereby amended as follows: 
 (a) Clause (ii) of the first sentence shall be deleted and the clauses following clause (ii) shall be renumbered, so that the first sentence
reads in its entirety as follows: 
 “ ‘Field of Use’ shall mean any [*] applications in [*] (including, but not limited
to, [*] during and following [*]) other than and hereby expressly excluding applications relating to: (i) the [*] and [*]; (ii) the [*], the [*] and the structures of the [*]; (iii) the [*]; and (iv) the [*] when access by [*]
means.” 
 (b) The following sentence shall be added after the last sentence: 
 “ ‘ENT Applications’ shall mean any [*] applications in [*] (including, but not limited to, [*] during and following [*]) relating
to the brain and the head and neck and [*] and [*] and [*] thereof (other than those of the [*] portion of the [*]).” 
 2. License
Grant. Section 2.1 shall be amended to read in its entirety as follows: 
 “Subject to the terms and conditions hereof,
Medtronic hereby grants to Licensee (a) a royalty-bearing and exclusive license under the Subject Technology, with the right to grant sublicenses subject to the terms of Section 2.2 hereof, to make, have made, use and sell Wet Electrode
Products in the Field of Use (other than Spinal Applications and ENT Applications) that are Licensed Products throughout the Territory, (b) royalty-bearing and co-exclusive license, subject to the rights retained by Medtronic and described in
the last sentence of this Section 2.1, under the Subject Technology, with no right to grant sublicenses to make, have 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 30 

 Execution Copy 
  
 made, use and sell Wet Electrode Products for Spinal Applications and ENT Applications in the Field of Use that are Licensed
Products throughout the Territory, and (c) a royalty-bearing and non-exclusive license under the Subject Technology, with the right to grant sublicenses subject to the terms of Section 2.2 hereof, to make, have made, use and sell Wet
Electrode Generators in the Field of Use that are Licensed Products throughout the Territory. Medtronic has no right to grant licenses or sublicenses to the Subject Technology to make, have made, use or sell Wet Electrode Products for Spinal
Applications or ENT Applications in the Field of Use that are Licensed Products in the Territory, provided, however, that Medtronic may grant one or more Permitted Spinal Product Licenses (as defined in Section 3.2) on or after
June 18, 2003 and that Medtronic may grant one or more Permitted ENT Product Licenses (as defined in Section 3.2) on or after July 18, 2007; provided, further, however, that subject to any confidentiality limitations applicable
to Medtronic in connection with such grant, Medtronic shall give Licensee notice of the granting of any Permitted Spinal Product License or any Permitted ENT Product License within fifteen (15) days of the effective date of such grant, (such
notice to identify the license or sublicense and the litigation or dispute relating to such grant and to describe the scope of the license in reasonable detail), and shall provide Licensee with additional information upon reasonable request in order
to enable Licensee to verify that such license or sublicense was granted in accordance with the terms of this Agreement.” 
 3.
Royalty on ENT Licensed Products. Section 3.2 shall be amended as follows: 
 (a) All references to “Net Sales of Licensed
Products excluding Spinal Licensed Products” shall be replaced with the phrase “Net Sales of Licensed Products excluding Spinal Licensed Products and ENT Licensed Products.” 
 (b) The following sentences shall be added after the last sentence of Section 3.2: 
 “For purposes of this Agreement, ENT Licensed Products’ shall mean Licensed Products marketed for ENT Applications. ‘Permitted
ENT Product License’ shall mean a license or sublicense to make, have made, use and sell Wet Electrode Products for ENT Applications in the Field of Use that are Licensed Products in the Territory granted by Medtronic to a third party that
is not an Affiliate of Medtronic as is necessary or appropriate (as determined by Medtronic in its sole discretion) solely for the purpose of settling litigation between Medtronic and the third party relating to Medtronic’s intellectual
property rights or settling another bona fide dispute between Medtronic and the third party relating to Medtronic’s intellectual property rights. Subject to the terms of this Agreement, Licensee shall pay to Medtronic a royalty equal to the
applicable percentage of Net Sales of ENT Licensed Products set forth in paragraphs (e) – (h) of this Section 3.2 (calculated as if the reference to Net Sales of Spinal Licensed Products in such paragraphs instead referred to Net
Sales of ENT Licensed Products).” 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 31 

 Execution Copy 
  
 4. Minimum Royalties. Section 3.3 shall be amended as follows: 
 (a) The phrase “Royalties on Net Sales of Licensed Products excluding Spinal Licensed Products” in the fourth sentence shall be replaced with
the phrase “Royalties on Net Sales of Licensed Products excluding Spinal Licensed Products and ENT Licensed Products.” 
 (b) The
phrase “calendar years 2004, 2005 and 2006” in the fifth sentence shall be replaced with the phrase “calendar years 2004, 2005, 2006, 2007 and 2008.” 
 (c) The phrase “January 1, 2007” in the last sentence shall be replaced with the phrase “January 1, 2009.” 
 5. Royalty Payments. Section 3.4 shall be amended as follows: 
 (a) The phrase “January 1,
2004 through December 31, 2006” in the third sentence shall be replaced with the phrase “January 1, 2004 through December 31, 2008.” 
 (b) The phrase “multiplied by .05” in the second to last sentence shall be replaced with the phrase “multiplied by .08.” 
 (c) The phrase “January 1, 2007” in the last sentence shall be replaced with the phrase “January 1, 2009.” 
 6. Exhibit A. Exhibit A to the License Agreement (Form Promissory Note) shall be amended as follows: 
 (a) The phrase “March 31, 2007” in the second paragraph shall be replaced with the phrase “March 31, 2009.” 
 (b) The phrase “ten percent (10%)” in the second paragraph shall be replaced with the phrase “eleven and three-quarters percent
(11.75%).” 
 (c) The phrase “that certain Amendment No. 2 to License Agreement dated March 1, 2004 (the
‘Amendment’)” in the first full paragraph on page 4 shall be replaced with the phrase “that certain Amendment No. 2 to License Agreement dated March 1, 2004 and Amendment No. 3 to License Agreement dated
July 18, 2006 (collectively, the ‘Amendment’).” 
 7. Warrant Issuance. As additional consideration for this
Amendment No. 3, Licensee shall execute and deliver to Medtronic a warrant on the terms and in the form of the Form Warrant for that number of shares equal to (A) the aggregate amount of promissory notes issued by Licensee to Medtronic
outstanding as of the date hereof multiplied by .03; divided by (B) 1.263. 
 8. Miscellaneous. Except as otherwise
expressly amended by this Amendment No. 3, the terms of the License Agreement shall remain in full force and effect. This Amendment may be executed in any number of counterparts, each of which shall be deemed as original, but all of which
together shall constitute one and the instrument. 
 [Signature page follows.] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 32 

 IN WITNESS WHEREOF, each of the parties has caused this Amendment No. 3 to License Agreement to be
executed in the manner appropriate for each, and to be dated as of the date first above-written. 
  

			
	TISSUELINK MEDICAL, INC.
		
	By:	 	 /s/ M. Jacqueline Eastwood

	Name:	 	M. Jacqueline Eastwood
	Title:	 	Pres. & CEO
	
	MEDTRONIC, INC.
		
	By:	 	 /s/ Michael D. Ellwein

	Name:	 	Michael D. Ellwein
	Title:	 	VP & CDO

  

  
  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 AMENDMENT NO. 4 
 TO 
 LICENSE AGREEMENT 
 THIS AMENDMENT NO. 4 TO LICENSE AGREEMENT (the “Amendment”) is entered into as of April 1, 2007 (the “Effective Date”), by and
between TissueLink Medical, Inc. (“Licensee”) and Medtronic, Inc., and it amends that certain License Agreement dated as of August 9, 1999 between the parties as amended by Amendment No. 1 to License Agreement dated June 18,
2002, Amendment No. 2 to License Agreement dated March 1, 2004 and Amendment No. 3 to License Agreement dated July 18, 2006 (the “License Agreement”). 
 The parties hereby agree that the License Agreement is amended as follows: 
 1. Field of Use. Section 1.5 of the License Agreement is hereby amended so that the first sentence reads in its entirety as follows: 
 “ ‘Field of Use’ shall mean any [*] applications in [*] (including, but not limited to, [*]) other than and hereby expressly
excluding applications relating to: (i) the [*] and [*]; (ii) the [*], the [*] and the [*] of the [*]; (iii) the [*]; and (iv) the accessing of any of the [*] described in clauses (i) – (iii) above by means of the
[*]. 
 2. Licensed Products. Section 1.7 of the License Agreement is hereby amended so that it reads in its entirety as follows:

 “Licensed Products” shall mean Wet Electrode Products, Interstitial Needle Products and Wet Electrode Generators, the
manufacture, use or sale of which uses or incorporates any of the Subject Technology.” 
 2. Subject Technology. 
 (a) Section 1.11(iii) of the License Agreement is hereby amended so that it reads in its entirety as follows: 
 “(iii) all invention disclosures, trade secrets and know-how owned by Medtronic prior to the date of this Agreement that relate specifically to the
Wet Electrode Products, Interstitial Needle Products (as defined in Section 3.2) or Wet Electrode Generators disclosed in the patents and patent applications listed in Exhibit A and” 
 (b) Exhibit A of the License Agreement shall be amended to add those patents listed on Schedule 1 of this Amendment. 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 34 

 3. Wet Electrode Generator(s). Section 1.13 of the License Agreement is hereby amended so
that it reads in its entirety as follows: 
 “Wet Electrode Generator(s)” shall mean the medical generators
primarily intended to provide power directly to Wet Electrode Products or Interstitial Needle Products in the Field of Use.” 
 4.
License Grant. Section 2.1 shall be amended to read in its entirety as follows: 
 “Subject to the terms and conditions
hereof, Medtronic hereby grants to Licensee (a) a royalty-bearing and exclusive license under the Subject Technology, with the right to grant sublicenses subject to the terms of Section 2.2 hereof, to make, have made, use and sell Wet
Electrode Products in the Field of Use (other than Spinal Applications and ENT Applications) that are Licensed Products throughout the Territory, (b) a royalty-bearing and co-exclusive license, subject to the rights retained by Medtronic and
described in the last sentence of this Section 2.1, under the Subject Technology, with no right to grant sublicenses, to make, have made, use and sell Wet Electrode Products for Spinal Applications and ENT Applications in the Field of Use that
are Licensed Products throughout the Territory, (c) a royalty-bearing and co-exclusive license, subject to the rights retained by Medtronic and described in the last sentence of this Section 2.1, under the Subject Technology, with no right
to grant sublicenses, to make, have made, use and sell Interstitial Needle Products in the Field of Use that are Licensed Products throughout the Territory and (d) a royalty-bearing and non-exclusive license under the Subject Technology, with
the right to grant sublicenses subject to the terms of Section 2.2 hereof, to make, have made, use and sell Wet Electrode Generators in the Field of Use that are Licensed Products throughout the Territory. Medtronic has no right to grant
licenses or sublicenses to the Subject Technology to make, have made, use or sell (i) Wet Electrode Products for Spinal Applications or ENT Applications in the Field of Use that are Licensed Products in the Territory or (ii) Interstitial
Needle Products in the Field of Use that are Licensed Products in the Territory, provided, however, that Medtronic may grant one or more Permitted Spinal Product Licenses (as defined in Section 3.2) on or after June 18, 2003, one or
more Permitted ENT Product Licenses (as defined in Section 3.2) on or after July 18, 2007, and one or more Permitted Interstitial Needle Product Licenses (as defined in Section 3.2) on or after April 1, 2008; provided,
further, however, that subject to any confidentiality limitations applicable to Medtronic in connection with such grant, Medtronic shall give Licensee notice of the granting of any Permitted Spinal Product License, Permitted ENT Product License
or Permitted Interstitial Needle Product License within fifteen (15) days of the effective date of such grant, (such notice to identify the licensee or sublicensee and the litigation or dispute relating to such grant and to describe the scope
of the license in reasonable detail), and shall provide Licensee with additional information upon reasonable request in order to enable Licensee to verify that such license or sublicense was granted in accordance with the terms of this
Agreement.” 
 5. Royalty on Interstitial Needle Products. Section 3.2 shall be amended so that the following sentences
shall be added after the last sentence of Section 3.2: 
 “For purposes of this Agreement, ‘Interstitial Needle
Products’ shall mean any interstitial needle or intraluminal wire devices or products. ‘Permitted Interstitial Needle Product License’ shall mean a license or sublicense to make, have made, 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 35 

 use and sell Interstitial Needle Products in the Field of Use that are Licensed Products in the Territory
granted by Medtronic to a third party that is not an Affiliate of Medtronic as is necessary or appropriate (as determined by Medtronic in its sole discretion) solely for the purpose of settling litigation between Medtronic and the third party
relating to Medtronic’s intellectual property rights or settling another bona fide dispute between Medtronic and the third party relating to Medtronic’s intellectual property rights. Subject to the terms of this Agreement, Licensee shall
pay to Medtronic a royalty equal to [*] percent ([*]%) of Net Sales of Interstitial Needle Products that are Licensed Products by Licensee and by any sublicensee, Affiliate or third party permitted under Section 2.2.” 
 6. Minimum Royalties. Section 3.3 shall be amended so that the phrase “Royalties on Net Sales of Licensed Products excluding Spinal
Licensed Products and ENT Licensed Products” in the fourth sentence shall be replaced with the phrase “Royalties on Net Sales of Licensed Products excluding Spinal Licensed Products, ENT Licensed Products and Interstitial Needle
Products.” 
 7. Correction to Titles of Exhibits. The last sentence of Section 3.3 of the License Agreement, Section 1
of Amendment No. 2 to License Agreement and Section 6 of Amendment No. 3 to License Agreement shall be amended so that all references to “Exhibit A” are changed to read “Exhibit C,” and all references to
“Exhibit B” are changed to read “Exhibit D.” 
 8. Medtronic Right to Designate Director. In partial consideration
of Medtronic, Inc.’s execution of this Amendment No. 4, Licensee represents and warrants to Medtronic, Inc. that Licensee has caused its Amended and Restated Certificate of Incorporation to be amended, to the extent necessary, to provide
Medtronic, Inc. with a right to designate one (1) member of the Board of Directors of Licensee. Such right shall continue in effect until the earliest to occur of (i) the consummation of a Qualified Initial Public Offering (as defined in
such Amended and Restated Certificate of Incorporation), (ii) a Deemed Liquidation Event (as defined in such Amended and Restated Certificate of Incorporation) or (iii) the expiration or termination of the License Agreement. 
 9. Miscellaneous. Except as otherwise expressly amended by this Amendment the terms of the License Agreement shall remain in full force and
effect. This Amendment may be executed in any number of counterparts, each of which shall be deemed as original, but all of which together shall constitute one and the instrument. 
 [Signature page follows.] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 36 

 IN WITNESS WHEREOF, each of the parties has caused this Amendment No. 4 to License Agreement to be
executed in the manner appropriate for each, and to be dated as of the date first above-written. 
  

			
	TISSUELINK MEDICAL, INC.
		
	By:	 	 /s/ Joseph Army

	Name:	 	Joseph Army
	Title:	 	Chief Operations Officer
	
	MEDTRONIC, INC.
		
	By:	 	 /s/ Gary L. Ellis

	Name:	 	Gary L. Ellis
	Title:	 	Chief Financial Officer

  
  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 Schedule 1 
 Interstitial Needle Patents 
 To Be Added to Exhibit A 
  

							
	 Title
	 	 Serial No.
	 	 Filing Date
	 	 Patent No.

	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]

 [*] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.Services Agreement between the Registrant and Aubrey Group, Inc.

 Exhibit 10.25 
 SERVICES AGREEMENT 
 This Services Agreement (the “Agreement”) is entered into as of
this 29th day of April, 2008 (the “Effective Date”), by and between Salient Surgical Technologies, Inc., a Delaware corporation, having its principal place of business at One Washington Center, Suite 400, Dover, NH 03820 (fax:
603-742-1488) (“Customer”), and Aubrey Group, Inc., a California corporation, having its principal place of business at 6 Cromwell, Suite 100, Irvine, CA 92618 (fax: 949-581-0177) (“Aubrey Group”). 
 WHEREAS, Customer wishes to contract for the development of the Product (as defined below); 
 WHEREAS, Aubrey Group is engaged in the business of developing medical devices, including electrosurgical generators, and desires to develop the Product
on the terms and conditions set forth in this Agreement; 
 WHEREAS, Customer and Aubrey Group will work together as a team, providing needed
information to each other, communicating clear project objectives and product requirements, apprising each other of the status of their tasks, providing access to each other’s team members and facilities, and supporting each other’s tasks;
and 
 WHEREAS, Aubrey Group shall work with other third-party developers of Customer in the development of the Product; 
 NOW THEREFORE, the parties agree as follows: 
  

	1.	Development Activities 

 1.1. “Product” means the
Salient electrosurgical generator product, including the accompanying accessories, instructions for use and other documentation for such product, as described in detail in Exhibit A. 
 1.2. Development Services. Aubrey Group will provide to Customer the services set forth on Exhibit A (the “Development Services”). Aubrey Group
shall, from time to time upon Customer’s request, provide any updates, data and other information requested by Customer regarding the Development Services. Aubrey Group will perform such services using due diligence, best efforts, and
commercially reasonable judgment in compliance with Quality System Regulations and Guidance of the Food and Drug Administration. Due to unknowns inherent in the development of new products, but without limiting, in any way, any of Aubrey
Group’s enumerated contractual obligations under this Agreement, Aubrey Group guarantees no specific final outcome to Customer. Aubrey Group will provide adequate time to fulfill the service requirements. Customer and Aubrey Group acknowledge
that detailed requirements are not fully known at this time and will be developed as the project progresses. 
 1.3. Ownership of Work Product.
Customer shall own all Product Specifications, Design History Files, Prototypes, regulatory submissions and approvals, and all other work, reports, writings, designs, embodiments, data and all other information that are acquired, collected, created,
developed, generated, written or otherwise made in the course of performance under this Agreement by either party or any third parties or agents acting on its behalf. 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 1 

 1.4. Changes. In case of deviations from the development plan set forth on Exhibit A, Aubrey Group shall,
on as timely basis as practicable, inform Customer of any deviations that could have a material change in scope or cost. Aubrey Group will discuss these deviations with Customer, and Customer will have the right to either accept such deviations from
scope or cost or, if the parties cannot reach another agreement, terminate the project in accordance with Section 3.4. 
 1.5. Design Payments.

 (a) All work will be done on a time-and-materials basis. The estimated labor, costs, and project schedule set forth on Exhibit A are
good faith, reasonable estimates prepared by Aubrey Group, but are not intended to be binding. 
 (b) Customer will pay Aubrey Group the
hourly fees specified on Exhibit D. 
 (c) To initiate services, Customer shall make a deposit of [*] to Aubrey Group. The deposit will
be applied to the project’s final invoice(s) with the remaining balance, if any, returned to Customer within 15 days of the final billing. Any unearned portion of such deposit will be returned to Customer by Aubrey Group in the event that this
Agreement is terminated by Customer in accordance with Section 3.3. 
 (d) Aubrey Group shall invoice Customer for work performed on a
weekly basis. Invoices will show time expended and costs incurred. Hourly fees and material costs shall be as listed on Exhibit A through the remainder of 2008. Once the initial scope of work as set out in Exhibit A is completed,
hourly rates may be adjusted by Aubrey Group from time to time to its then current standard rates, but no more often than annually. Customer shall pay such invoices no later than thirty (30) days after the receipt of an invoice. If requested,
Customer will increase the deposit to compensate for amounts regularly paid past the 30 day due date if any. Invoices not paid within such thirty (30) day period will be subject to a finance change of 1% per month, other than to the extent
subject to a good faith payment dispute. If Aubrey Group undertakes collection or enforcement efforts, Customer will pay for all costs thereof, including attorney’s fees. 
 (e) Customer will reimburse Aubrey Group for expenses incurred on behalf of Customer. Travel expenses will be billed at actual cost. Travel time will be
billed at standard rates not to exceed a total of eight hours per travel day. Travel time will be reduced to the extent travel time plus professional services exceed eight hours in the same day. All other expenses will be billed at cost plus a [*]
fee. Individual purchase orders for expenses totaling over [*], if any, at Customer’s option will be identified in advance and submitted for approval before they are incurred. Aubrey Group, at its option, may require prepayment of individual
purchase orders for expenses over [*] before they are incurred. Unless otherwise specified by Customer, California sales and use taxes will be paid for by Aubrey Group for all parts and tools for the project and included in billed costs of parts and
tools on invoices. 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 2 

 1.6. Customer Control. 
 (a) In the provision of the Development Services and throughout the term of this Agreement, Aubrey Group shall, at the request of Customer, integrate all comments and suggestions made by Customer regarding the design
of the Product. Upon the request of Customer, Aubrey Group shall apply for and obtain the Product’s UL certification and any other regulatory or industry approvals or markings. Aubrey Group will cooperate with Customer in connection with
Customer’s FDA and CE mark regulatory filings and other regulatory and industry approval applications, including making available Aubrey Group’s Confidential Information to such regulatory agencies to the extent required to obtain approval
of the Product. 
 (b) If so directed by Customer, Aubrey Group will cease all or any activities being performed by Aubrey Group hereunder and
shall cease incurring any fees or expenses related to such activities as soon as practicable after appropriate notice has been given pursuant to Section 3.4. 
 (c) The Development Services shall include the delivery of final product specifications (“Product Specifications”) to Customer. 
 1.7. Prototypes. Aubrey Group shall deliver to Customer, for Customer’s inspection, a minimum of ten (10) units of prototypes of Product (“Prototypes”). 
 1.8. Compliance. Aubrey Group will perform the Development Services in accordance with (i) Good Manufacturing Practices (as defined in Section 4.1) and
Quality Systems (as defined in Section 4.6) and all other pertinent rules and regulations of the Food and Drug Administration (the “FDA”); (ii) applicable international standards, including CE (European Community) mark standards
for medical devices; and (iii) Customer’s Engineering Change Process Standard Operating Procedures (“SOP”) as listed on Exhibit B; each of (i) through (iii) as may be updated from time to time. Upon the request
of Customer, Aubrey Group shall provide Customer with written evidence of compliance with the criteria set forth in the preceding sentence. 
 1.9. Later
Revealed Design Defects. In the event that, after the delivery of the Product Specifications to Customer, it is determined that a defect in the Product Specifications is adversely affecting the normal operation of the Product, Aubrey Group
shall, at its then current rates at Customer’s expense, revise the Product Specifications in cooperation with Customer to eliminate such operational problem. 
  

	2.	Intellectual Property 

 2.1. Definitions. 
 (a) “Customer Pre-Existing Intellectual Property” means Intellectual Property owned or controlled by Customer prior to the date of this
Agreement (including all Intellectual Property related to the Product). 
 (b) “Aubrey Group Pre-Existing Intellectual Property”
means Intellectual Property owned or controlled by Aubrey Group prior to the date of this Agreement. 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 3 

 (c) “New Intellectual Property” means Intellectual Property that is conceived, reduced to
practice or made in the course of performance under this Agreement by Aubrey Group or third parties or agents acting on its behalf. 
 (d)
“Intellectual Property” means all inventions, discoveries, data, information, processes, methods, compositions of matter, articles of manufacture, software, techniques, materials, technology, trade secrets, copyright rights in any and all
copyrightable works, results, improvements, know-how and other intellectual property rights, whether or not patentable. 
 2.2. Pre-Existing Intellectual
Property Ownership. Customer owns and shall own all Customer Pre-Existing Intellectual Property, and Aubrey Group owns and shall own all Aubrey Group Pre-Existing Intellectual Property. 
 2.3. New Intellectual Property. Customer owns and shall own all New Intellectual Property. Customer hereby grants to Aubrey Group, with no right to sublicense, a
non-exclusive, royalty-free, perpetual, irrevocable, worldwide license to use New Intellectual Property (other than improvements to Customer Pre-Existing Intellectual Property) to make and design products other than (i) the Product and
(ii) electrosurgical generators and/or handheld devices for other liquid-cooled radio frequency energy products; provided, however, that this license grant shall terminate in the event that this Agreement is terminated by Customer
in accordance with Section 3.3. 
 2.4. License to Customer. Aubrey Group hereby grants to Customer, with the right to grant sublicenses to its
affiliates and third parties acting on Customer’s behalf, a non-exclusive, royalty-free, perpetual, irrevocable, worldwide license under all Intellectual Property of Aubrey Group utilized in the course of performance under this Agreement or
incorporated into the Product Specifications, to make, have made, use, sell, have sold, import and otherwise commercialize the Product, accessories for the Product, hand-held devices and other Customer products used in connection with the Product
and updated or improved versions of the Product; provided, however, that this license grant shall terminate in the event that this Agreement is terminated by Aubrey Group in accordance with Section 3.3. 
 2.5. Further Assurances. To the extent necessary to perfect or enforce Customer’s rights under this Section 2, Aubrey Group hereby assigns and agrees to
assign to Customer all of its right, title and interest in and to all New Intellectual Property. Aubrey Group agrees to cooperate with Customer and to execute and deliver any and all documents that are reasonably necessary to perfect and enforce
Customer’s rights hereunder, including reasonably cooperating in the preparation and prosecution of patent applications and acting in good faith in permitting disclosure of confidential information. Customer shall reimburse Aubrey Group for its
reasonable employee time required to comply with this Section 2.5 in accordance with the Aubrey Group’s then current standard hourly rates. 
 2.6.
Third Party IP. In the design of the Product and in the performance of its obligations under Section 1 or Section 3.5, Aubrey Group shall not knowingly use any third party intellectual property unless Aubrey Group has the right to
grant a fully-paid, worldwide license or sublicense to Customer in such third party intellectual property, with the right of Customer to further sublicense. 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 4 

 2.7. Survival. The terms of this Section 2 shall survive the expiration or termination of this Agreement, and
shall be binding upon and inure to the benefit of the successors and assigns of the parties. 
  

	3.	Term and Termination of the Agreement 

 3.1. Term. The term
of this Agreement shall begin on the date first set forth above and shall continue until the completion of all Development Services and Know-How Transfer to the reasonable satisfaction of Customer, unless otherwise terminated earlier in accordance
with the terms of this Agreement. 
 3.2. Termination by Either Party. This Agreement may be terminated by either party immediately upon notice to the
other party in the event of any of the following: 
 (a) the other party makes a general assignment for the benefit of its creditors, or a
receiver or similar officer is appointed to take charge of any of the other party’s assets; 
 (b) the other party ceases to carry on its
business or operations; and 
 (c) a bankruptcy or similar petition is filed by or against the other party, and in the case of an involuntary
petition, the proceeding is not dismissed within sixty (60) days. 
 3.3. Termination for Material Breach. Upon material breach by either party
of its obligations under this Agreement, the other party may terminate this Agreement if the breach remains uncured for more than thirty (30) days after a party gives written notice of the breach. 
 3.4. Termination for Convenience. Customer may terminate this Agreement for any reason or no reason upon thirty (30) days notice. Customer will pay Aubrey
Group’s reasonable time and materials charges during the notice period. The Aubrey Group will use its best efforts to mitigate its charges if Customer gives notice of termination. 
 3.5. Know-How Transfer. During the completion phase of the Development Services or the expiration or termination of this Agreement, Aubrey Group shall cooperate with Customer and provide all necessary
assistance to effect the orderly and efficient transfer of all know-how and documents relating to the design and manufacturing of the Product from Aubrey Group to Customer or a third party designated by Customer (“Know-How Transfer”).
Know-How Transfer shall include, but not be limited to, the items listed on Exhibit C. The provisions of this Section 3.5 shall survive the termination or expiration of this Agreement. 
 3.6. Technical Support. To assist Customer in diagnosing and resolving Product failures in the field, Aubrey Group agrees to provide reasonable technical support
to Customer for Product developed under this Agreement. at Customer’s expense and in accordance with the Aubrey Group’s then current standard hourly rates. The provisions of this Section 3.6 shall survive the termination or expiration
of this Agreement. 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 5 

	4.	Quality System Requirements 

 4.1. Registrations. Aubrey
Group shall obtain and maintain all registrations and approvals necessary for Aubrey Group to engage in the Development Services. Aubrey Group must remain compliant with the requirements set forth in 21 U.S.C. § 360J(f), 21 C.F.R. § 820,
all related guidance issued by the FDA, ISO 13485 (collectively, “Good Manufacturing Practices”). Aubrey Group’s performance of this Agreement shall be in compliance with these Good Manufacturing Practices. Customer shall own and hold
in its name all regulatory approvals related to the Product. 
 4.2. Inspections. Aubrey Group agrees to permit government officials, as required by
law, and, with three days prior notification, Customer or its authorized representative, to conduct inspections and test audits of Aubrey Group’s facilities, operations, and procedures, at appropriate and reasonable time intervals, to verify
that the quality and performance of the Development Services are in accordance with Exhibit A and Section 1.8. With three days prior notification, the Company may also inspect the facilities of Aubrey Group at any time during business
hours to ensure compliance with Good Manufacturing Practices. Aubrey Group shall cooperate with any inspection performed under this section. As pertinent to Customer’s Product, Aubrey Group shall implement corrective and preventative actions in
a timely manner to address nonconformances noted in audits by Customer, the FDA, ISO Registrar or other regulatory authorities. 
 4.3. Customer
Audits. With reasonable notice, Aubrey Group shall allow Customer and government officials to perform audits of, as they may be applicable to Customer’s Product, Aubrey Group’s Quality System, Good Manufacturing Practices, facilities,
records and all manufacturing documentation related to Customer’s Product or the Prototypes. Aubrey Group agrees to make appropriate Aubrey Group personnel available for audits at either Customer’s or Aubrey Group’s offices. All
reasonable expenses related to the conduct of inspection and test audits of the Product and/or Quality System (as defined below in Section 4.6) by Customer or, if Customer so chooses, a qualified third party, shall be borne by Customer. Such
audits and inspections must take place during normal business hours and with reasonable notice. 
 4.4. Regulatory Audits. If the facilities or
processes of Aubrey Group are inspected or audited by any regulatory agency such as but not limited to the FDA, OSHA, EPA, CE Notified Body or ISO Registrar, Aubrey Group will determine the relevant implications, if any, to Customer’s Product;
and then, if appropriate, inform Customer of that fact and of all findings of such agency that relate to or affect the Product or Device Master Record, which includes all information necessary to produce the Product. If Aubrey Group determines that
there are no relevant implications to Customer’s Product with respect to any inspection or audit, it will provide a brief letter to Customer setting forth the reasoning behind such determination. 
 4.5. DMR. Aubrey Group shall supply all information requested by Customer to create and maintain the Device Master Record for the Product. 
 4.6. QSR. Aubrey Group shall maintain a quality system in accordance with ISO 13485 certification and 21 C.F.R. § 820 Quality System Regulations compliance
(“Quality System”). All activities performed on behalf of Customer shall be performed in accordance with these regulations and standards. Aubrey Group shall maintain and retain Product quality related records, such as any records of system
or instrument tests, for five (5) years. Aubrey Group shall contact Customer and provide the option of transferring records older than five (5) years to Customer’s location. 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 6 

 4.7. Approved Suppliers. Aubrey Group shall maintain a list of original components and service suppliers that they
have approved (“Approved Suppliers”). Aubrey Group shall purchase materials and services to be used in Customer’s Product for sale only from Approved Suppliers. Approved Suppliers must have passed Aubrey Group’s supplier
evaluation process. Aubrey Group shall work with its Approved Suppliers to allow Customer to perform on-site audits of its Approved Suppliers, as requested, at mutually agreed upon times. Aubrey Group shall assist Approved Suppliers in providing
corrective action to remedy any deficiencies observed during the audit, and make such actions available to Customer. Customer reserves the right to reject any Approved Supplier, and Aubrey Group shall not purchase components from such rejected
suppliers in the manufacture of Product or the Prototypes. 
 4.8. No Debarment. Aubrey Group represents, warrants and covenants that it is not
currently using, and will not in the future use, in any capacity, in connection with the performance of its duties or obligations hereunder, the services of any person debarred or subject to debarment under 21 U.S.C. § 335(a) or otherwise
disqualified or suspended from performing services or otherwise subject to any restrictions or sanctions by the FDA or any other regulatory authority or professional body (a “Debarred Person”). Aubrey Group shall immediately notify
Customer in writing if any person or entity who is performing services on its behalf hereunder is or becomes a Debarred Person or if any action, claim, investigation, or other legal or administrative proceeding is pending or, to the best of Aubrey
Group’s knowledge, threatened, that would make any person performing services hereunder a Debarred Person or would preclude Aubrey Group from performing its obligations under this Agreement. Aubrey Group shall require all persons and entities
providing services under this Agreement to make substantially the same warranty and covenant. 
 4.9. Regulatory Action. If the FDA or another
regulatory authority (a) contacts Aubrey Group with respect to the development of the Product, (b) conducts, or gives notice of its intent to conduct, an inspection of the facilities of Aubrey Group being used for the development of the
Product, or (c) takes, or gives notice of its intent to take, any other regulatory action alleging improper or inadequate practices with respect to any activity of Aubrey Group, then Aubrey Group shall supply Customer with all information
pertinent thereto. Customer shall have the right to be present at and to participate in any such inspection or regulatory action with respect to the Product. Customer shall be provided with copies of all documentation issued by the FDA or any other
regulatory authority in connection therewith and any proposed responses thereto. No such response shall include any false or misleading information with respect to the Product or Customer. 
 4.10. Medical Device Reporting. Customer shall be solely responsible for reporting all medical device and malfunction reports as defined in 21 C.F.R. § 820,
relating to the Product. To the extent Aubrey Group has or receives any information regarding any medical device and malfunction report that may be related to the use of the Product, Aubrey Group shall immediately, and in no event later than two
(2) business days of receipt by Aubrey Group, provide Customer with all such information. 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 7 

	5.	Indemnification 

 5.1. Customer and Aubrey Group agree that each
will not be liable to the other, the other’s customers or employees for any damages resulting from any errors claimed to have been committed by the other. As the developer of the final product, Customer accepts all risk of personal injuries and
damages, and Customer specifically releases Aubrey Group from any liabilities relating to the performance of services for Customer. Notwithstanding the foregoing two sentences, neither party shall be released from liability with respect to
liabilities found to result from such party’s gross negligence, fraud, or willful misconduct. 
 5.2. Customer agrees to defend and indemnify Aubrey
Group from and against any claim, liability, or action by any third party against Aubrey Group relating to Aubrey Group’s services performed under this Agreement, other than liabilities found to result from Aubrey Group’s gross negligence,
fraud, or willful misconduct. 
  

	6.	Insurance 

 6.1. Aubrey Group shall maintain during the term of this
Agreement insurance in amounts and types adequate for the size and character of its business, and comparable to companies of similar size and character, including the following minimum insurance requirements: 
 (a) Commercial General Liability and Products Insurance of not less than $1 million per occurrence, $2 million in aggregate. 
 (b) Worker’s Compensation Insurance in amounts of not less than as required in accordance with applicable law. 
 6.2. Customer certifies that it now carries and intends to continue product liability insurance with a limit of at least $2 million per occurrence and in the aggregate.
Customer agrees to include Aubrey Group as an additional insured on its product liability insurance policy, with respect to Aubrey Group’s services provided under this Agreement. 
 6.3. Each party shall provide the other party with thirty (30) days written notice prior to any cancellation or change of coverage provided that comparable insurance is not purchased from another carrier. Each
party shall deliver certificates of insurance evidencing such coverage to the other party on or before the Effective Date, and upon request thereafter. 
  

	7.	Limitation of Liability 

 7.1. EXCEPT AS SET FORTH OTHERWISE IN THIS
AGREEMENT OR CLAIMS ARISING FROM ANY INDEMNIFICATION OBLIGATIONS SET FORTH IN SECTION 5, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES OF ANY KIND OR NATURE ARISING OUT OF THIS
AGREEMENT OR THE SALE OF PRODUCT, WHETHER SUCH LIABILITY IS ASSERTED ON THE BASIS OF CONTRACT, TORT (INCLUDING THE POSSIBILITY OF NEGLIGENCE OR STRICT LIABILITY), OR OTHERWISE, EVEN IF THE PARTY HAS BEEN WARNED OF THE POSSIBILITY OF ANY SUCH LOSS OR
DAMAGE, AND EVEN IF ANY OF THE LIMITED REMEDIES IN THIS AGREEMENT FAIL OF THEIR ESSENTIAL PURPOSE. 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 8 

	8.	Confidentiality 

 8.1. “Confidential Information”
means any know-how, trade secrets or other confidential or proprietary information, including, without limitation, proprietary information and materials regarding a party’s technology, products, business information or objectives, disclosed or
otherwise communicated by one party (or agents or third parties acting on its behalf), to the other party, or agents or third parties acting on its behalf (in any form, whether written, oral, photographic, electronic, magnetic, or otherwise),
before, on, or after the date hereof, and whether or not such know-how, trade secrets or other information is identified as confidential at the time of disclosure. 
 Any data and information relating to the Product generated by either party pursuant to this Agreement, including, without limitation, information relating to the design of or manufacturing process for the Product, Product Specifications,
Device Master Records, Design History Files, Product pricing, design materials, development facilities and capabilities, equipment, techniques and plans related to the Product, production quantities and capacities, product development, market
information, commercial and regulatory timelines, and plans and approvals, shall be deemed to be Confidential Information of Customer. 
 Notwithstanding the
foregoing, Confidential Information shall not include any information that: (i) at the time of disclosure was already known to the receiving party, as demonstrated by documents or other competent evidence, other than information received from a
third party bound by an obligation of confidentiality to the disclosing party; (ii) is disclosed in published literature, or otherwise generally known to the public through no breach of this Agreement by the receiving party; (iii) is
obtained by the receiving party from a third party not in violation of any obligation of confidentiality to the party whose Confidential Information is at issue; or (iv) as demonstrated by documents or other competent evidence, was
independently developed by the receiving party without reference to or use of the other party’s Confidential Information. 
 8.2. Aubrey Group
Confidentiality Obligations. Aubrey Group shall not disclose Confidential Information of Customer to any third party other than: 
 (a)
its employees who are bound by obligations of confidentiality and nonuse no less restrictive than those set forth in this Agreement, and who have a need to know such information in order to perform their duties in carrying out Aubrey Group’s
obligations under this Agreement; 
 (b) consultants, agents or subcontractors used by Aubrey Group pursuant to Section 4.7 who are bound
by obligations of confidentiality and nonuse no less restrictive than those set forth in this Agreement, and who have a need to know such information in order to provide direction to Aubrey Group or Customer regarding their respective obligations
under this Agreements or in order to (i) perform their duties in carrying out Aubrey Group’s obligations under this Agreement, or (ii) provide direction to Aubrey Group regarding the subject matter of this Agreement; or 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 9 

 (c) with the prior consent of Customer, regulatory authorities, for example, the FDA, that require such
information in order to review a regulatory filing for a Product. 
 8.3. Customer Confidentiality Obligations. Customer shall not disclose
Confidential Information of Aubrey Group to any third party other than: 
 (a) employees, consultants, agents or subcontractors of Customer
who are bound by obligations of confidentiality and nonuse no less restrictive than those set forth in this Agreement, and who have a need to know such information in order to provide direction to Customer regarding its obligations under this
Agreement or in order to provide direction to Customer regarding the subject matter of this Agreement, including, but not limited to (i) design, production, testing, storage or quality of the Product or regulatory or compliance issues related
to the Product and (ii) design, production, testing, storage or quality of accessories for the Product, hand-held devices or other Customer products used in connection with the Product or updated or improved versions of the Product, or
regulatory or compliance issues related to such items; or 
 (b) regulatory authorities, for example, the FDA, that require such information
in order to review a regulatory filing for a Product. 
 8.4. Terms of Agreement. Subject to Section 8.5 (Notification of Mandatory Disclosure)
hereof, neither party shall, without the prior written consent of the other party, disclose in any manner to any third party the specific terms and conditions of this Agreement. 
 8.5. Notification of Mandatory Disclosure. 
 (a) Notification and Consultation. In the event
that a party (in such case, the “Notifying Party”) believes it is required by applicable statute or regulation, or by judicial or administrative process to disclose any part of the other party’s (in such case, the “Notified
Party”) Confidential Information which is disclosed to it under this Agreement, the Notifying Party shall (i) promptly notify the Notified Party of each such requirement and identify the documents so required thereby, so that the Notified
Party may seek an appropriate protective order or other remedy and/or waive compliance by the Notifying Party with the provisions of this Agreement and (ii) consult with the Notified Party on the advisability of taking legally available steps
to resist or narrow the scope of such requirement. 
 (b) Limited Disclosure. If, in the absence of such a protective order or such a
waiver by the Notified Party of the provisions of this Agreement, the Notifying Party is nonetheless required by mandatory applicable law to disclose any part of the Notified Party’s Confidential Information which is disclosed to it under this
Agreement, the Notifying Party may disclose such Confidential Information without liability under this Agreement, except that the Notifying Party shall furnish only that portion of the Confidential Information which it reasonably believes is legally
required to be disclosed. 
 (c) SEC Regulations. Notwithstanding the foregoing or Section 8.4, Customer may disclose a copy of
and the terms of this Agreement (i) to comply with applicable securities laws, including the rules and regulations promulgated by the SEC and (ii) in connection with any due diligence investigation regarding a securities offering, change
in control transaction or the entering into 

  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 10 

 
of a credit agreement, to investment banks, private equity or venture capital funds, lending institutions or underwriters (or the consultants or legal
counsel of the foregoing), in each case (i) and (ii) without the need to comply with the provisions of this Section 8. 
  

	8.6.	Maintenance of Confidentiality; Nonuse Obligations. 

 (a) Maintenance of Confidentiality. Each party shall use reasonable and customary precautions to safeguard the other party’s Confidential Information, including ensuring that all employees, consultants, agents or contractors who
are provided access to such Confidential Information are informed of the confidential and proprietary nature of such Confidential Information and have confidentiality and nonuse obligations that are at least as restrictive as those contained in this
Agreement. 
 (b) Nonuse Obligations. Aubrey Group shall not use Customer’s Confidential Information for any purpose other than
performing its obligations under this Agreement, without first obtaining Customer’s prior written consent to such utilization. Customer shall not use Aubrey Group’s Confidential Information for any purpose other than performing its
obligations under this Agreement or in connection with the manufacturing, research or development of the Product and related products, including, but not limited to (i) design, production, testing, storage or quality of the Product or
regulatory or compliance issues related to the Product and (ii) design, production, testing, storage or quality of accessories for the Product, hand-held devices or other Customer products used in connection with the Product or updated or
improved versions of the Product or regulatory or compliance issues related to such items, without first obtaining Aubrey Group’s prior written consent to such utilization. 
 8.7. Use of Names. No party shall make use of the name of any other party in any advertising or promotional material, or otherwise, in connection with this Agreement or any related agreements, without the prior
written consent of such other party, which shall not be unreasonably withheld; provided, however, either party may include the name of the other party on a general list of business partners, suppliers or customers. 
 8.8. Survival of Confidentiality Obligations. The confidentiality provisions of Section 8.3 shall survive the termination or expiration of this Agreement for
a period of five years from the disclosure of Confidential Information. 
  

	9.	Miscellaneous 

 9.1. Compliance with Laws and Permitting.
Each party agrees that its performance under this Agreement shall comply with all applicable laws. Aubrey Group shall, at its expense, obtain and maintain all necessary permits and licenses required for the operation of its development and
manufacturing facilities and processes. 
 9.2. No Conflicts. As of the Effective Date, each of Customer and Aubrey Group hereby represent and warrant
to the other party hereto that the execution, delivery and performance by such party of this Agreement and its compliance with the terms and provisions hereof does not and shall not conflict with or result in a breach of any of the terms and
provisions of or constitute a default under (i) any agreement or instrument binding or affecting it or its property or (ii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of
its property is bound. 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 11 

 9.3. Successors; Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto
and their respective successors, permitted assigns and legal representatives. Neither party shall have the right to assign or otherwise transfer its rights or obligations under this Agreement in whole or in part to any third party without the prior
written consent of the other party. Nothing in this section shall prohibit Customer from assigning this Agreement to an entity acquiring all or substantially all of the business of Customer to which this Agreement relates. 
 9.4. Independent Contractor Status. The relationship between the parties to this Agreement is that of independent contractors. The parties to this Agreement are
not joint venturers, partners, principal and agent, or employer and employee, and have no other relationship other than independent contracting parties. Aubrey Group shall be responsible for the payment of any payroll taxes, self-employment taxes,
workers compensation insurance, social security and other taxes and contributions due in connection with the employees and agents of Aubrey Group. 
 9.5.
Non-Solicitation. Neither party shall, during the term of this Agreement nor during the two (2) year period following the termination or expiration of this Agreement, directly or indirectly solicit, induce, recruit or encourage any of
the other party’s employees who performed services under or in connection with this Agreement to leave such party’s employ; provided, however, the foregoing shall not apply to general advertisements or solicitations for
personnel that are not directed specifically to any of the other party’s employees nor to employees who have been discharged by the other party. 
 9.6.
Governing Law. This Agreement shall be governed by and interpreted under the laws of the State of California without regard to conflict of law provisions, and adjudicated with the exclusive jurisdiction of the courts in the State of
California. 
 9.7. Notices. All notices required or permitted under this Agreement must be made in writing and delivered in person, by facsimile, or
by certified or registered mail, postage prepaid, addressed to the Chief Executive Officer for Customer (with a copy sent to VP of Research & Development for Customer), or President for Aubrey Group, at the respective addresses at the
beginning of this Agreement, or such other address that is provided in writing by such party. Such notice shall be effective upon receipt if personally delivered or transmitted by facsimile, or on the third business day following the date of
mailing. 
 9.8. Amendments. This Agreement may be amended only by written consent of both parties, executed by their authorized representatives.

 9.9. Severability. Any provision of this Agreement that is invalid or unenforceable in any jurisdiction, shall, as to such jurisdiction, be
ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement in any other jurisdiction. 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 12 

 9.10. Headings. Headings contained in this Agreement are for convenience and reference purposes only and shall not
affect the meaning or interpretation of this Agreement. The Exhibits and other attachments to this Agreement are incorporated by reference into this Agreement and form an integral part thereof. 
 9.11. Subcontracting. This Agreement is for the exclusive benefit of Customer and Aubrey Group and is not for the benefit of any third party. Aubrey Group shall
not have the rights to subcontract the performance of any of its obligations under this Agreement without the express written consent of Customer. 
 9.12.
Survival. The provisions of Section 1.3 (Ownership of Work Product), Section 2 (Intellectual Property), Section 3.5 (Know-How Transfer), Section 3.6 (Technical Support), Section 5 (Indemnification), Section 7
(Limitation of Liability), Section 8 (Confidentiality) and Section 9 (Miscellaneous) shall survive the termination of this Agreement. All amounts due and payable by either party under this Agreement shall continue to be due and payable
despite termination of this Agreement. 
 9.13. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original and all of which together shall constitute one instrument. 
 [remainder of page intentionally left blank]

  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
 13 

 IN WITNESS WHEREOF, the parties hereto have as of the date first written above duly executed this
Services Agreement. 
  

									
	SALIENT SURGICAL TECHNOLOGIES, INC.	 		 	AUBREY GROUP, INC.
					
	By:	 	/s/ Mark Roby	 		 	By:	 	/s/ Vytas Pazemenas
	Name:	 	Mark Roby	 		 	Name:	 	Vytas Pazemenas
	Title:	 	VP / R&MD	 		 	Title:	 	President and CEO

  

 [Signature Page to Services Agreement] 
  
 [*] = Portions of this exhibit have been omitted
pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Exhibit A 
 Project Plan 
 [Detailed Design Plan and Product Specifications Omitted] [*] 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Exhibit B 
 Applicable Standard Operating Procedures 
 11-90-0203, Engineering Change Process 
 [Detailed SOP Description Omitted] [*] 
  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Exhibit C 
 Know-How Transfer 
 The Know-How Transfer shall include the delivery and provision of the following: 
  

	 	•	 	 All product specifications and design information 

  

	 	•	 	 All Intellectual Property incorporated into the Product Specifications 

  

	 	•	 	 All tooling, injection molds, thermoforming molds, and any fixtures (“Tooling”) and improvements to Tooling related exclusively to the Product or the
Prototypes 

  

	 	•	 	 Manufacturing process description 

  

	 	•	 	 All test method validation and/or qualification protocols and reports 

  

	 	•	 	 List of all raw materials including grades, sources, raw material specifications and raw material release test methods 

  

	 	•	 	 Equipment requirements (particularly for any unique equipment) 

  

	 	•	 	 Storage requirements 

  

	 	•	 	 [*] 

  

	 	•	 	 Packaging information including all components, specifications for components and sources 

  

	 	•	 	 Labeling information (package inserts, outserts, labels, artwork) including samples of all printed components 

  

	 	•	 	 Any additional information required for a regulatory submission or needed to respond to regulatory questions 

  

	 	•	 	 Reasonable access to and assistance from relevant technical personnel and follow-up via phone, e-mail and in-person meetings for a period of five (5) years.

  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Exhibit D 
 Aubrey Group Inc. 
 2008 Standard Billing Rates 
  
  

				
	 Billing Title
	  	2008
Standard
Rate
	 
	 Development Project / Contract Work
	  		
	 Chief Engineer / Sr. Engineering Fellow
	  	[	*]
	 Project Manager / Principal Systems Engineer
	  	[	*]
	 Principal Engineer
	  	[	*]
	 Senior Electronics Engineer
	  	[	*]
	 Senior Software Engineer
	  	[	*]
	 Senior Mechanical Engineer
	  	[	*]
	 Electronics Engineer
	  	[	*]
	 Software Engineer
	  	[	*]
	 Mechanical Engineer
	  	[	*]
	 Quality - Regulatory Affairs
	  	[	*]
	 PCB Design Engineer
	  	[	*]
	 Manufacturing Engineer
	  	[	*]
	 Mechanical Designer
	  	[	*]
	 Project Manager Associate
	  	[	*]
	 Manufacturing Planner Engineer
	  	[	*]
	 Components Engineer/Purchasing
	  	[	*]
	 Document Control Specialist
	  	[	*]
	 Technical Associate
	  	[	*]
	 Technician/Drafter
	  	[	*]
	 Quality Assurance - Inspection
	  	[	*]
	 Engineering Assembler
	  	[	*]
	 Manufacturing Assembler
	  	[	*]

  

  
 [*]
= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}]]